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Abstract
Cardiac Rehabilitation (CR) is an exercise-based program, aimed at improving ones’
cardiovascular health. A substantial majority of patients referred to CR do not enroll, complete, or
achieve clinical targets in the program due to patient-level factors. The objective of this thesis was
to investigate relationships between anxiety sensitivity (AnxS) and patient outcomes in CR. Selfreported questionnaires were completed across two time points, with patient information being
abstracted from medical records. Stakeholders associated with reducing the burden of AnxS in CR
were also identified using snow-ball sampling. Findings suggest that resting diastolic blood
pressure is associated with the interrelationships between AnxS, anxiety, and depression. A larger
sample size is needed to establish concrete relationships between AnxS and patient outcomes in
CR. This evidence may support the need to target AnxS for treatment. Stakeholders with high
power and influence may also be beneficial in implementing changes to CR guidelines, if
necessary.

Keywords: Cardiovascular Disease, Cardiac Rehabilitation, Exercise, Mental Health, Anxiety
Sensitivity, Anxiety, Depression, One Health
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Summary for Lay Audience
Cardiac Rehabilitation (CR) is an effective exercise-based program with the goal of improving the
cardiovascular health of its patients. Across Ontario, most patients who are referred to CR do not
fully participate, complete, or achieved guideline recommended targets of the program. Research
has shown that depression and anxiety play a role with these observations. Anxiety sensitivity
(AnxS) is a personality trait of interest that we believe may impact ones’ ability to obtain the full
benefits of CR. Individuals with high AnxS feel unsafe or threatened when they experience anxiety
related symptoms (i.e., increased heart rate). We explored whether individuals with high AnxS
would engage in less physical activity, less exercise, and not achieve guideline recommended
targets. We administered 5 self-reported questionnaires at two different times, separated by 6
weeks. We also collected clinical information from each patient’s medical record. We observed
that individuals with high AnxS, high symptoms of anxiety, and high symptoms of depression
were more likely to report an at-risk diastolic blood pressure. Establishing relationships between
AnxS and patient outcomes in CR may be important as research suggests that AnxS may be easier
to treat compared to other psychological factors. This study must be done with more participants
to make more accurate conclusions of our findings. We also identified stakeholders of high
influence and power who could potentially help reduce the burden of AnxS in CR. If after further
exploration AnxS shows evidence of impacting patient outcomes in CR, these stakeholders could
help treat AnxS in CR. This can be done by conducting research-based initiatives leading to the
modification of existing CR guidelines.
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Chapter 1
1.0.

Introduction

Cardiovascular diseases (CVD) are a class of disorders associated with the heart and the
vasculature, including coronary artery disease (CAD), ischemic stroke, heart failure, arrhythmia,
and heart valve disease.1 While mortality rates from CVD have trended downward in the last 30
years 2, the prevalence of people living with CVD has increased, thus subsequently increasing the
associated burden on society.3 Cardiac rehabilitation (CR) was first established in the 1970s and
is supported with strong evidence of reducing mortality and morbidity related to CVD in a costeffective manner.4,5

1.1.

Cardiovascular Rehabilitation and Secondary Prevention

Contemporary CR programming encompasses cardiovascular rehabilitation and secondary
prevention, including optimization of pharmacotherapy; for the purposes of this thesis, we will be
using the acronym “CR” to denote “cardiovascular rehabilitation and secondary prevention”. CR
programs are delivered by certified clinicians. The Canadian Guidelines for Cardiac Rehabilitation
and Cardiovascular Disease Prevention describe CR programs encompassing the following: 1.
Systematic patient referral processes; 2. Patient assessments; 3. Health behaviour interventions
and risk factor modifications; 4. Adaptations for program models to improve accessibility,
especially for under-served populations; 5. Development of self-management techniques based
around individualized assessment, problem-solving, goal setting and follow up; 6. Exercise
training; 7. Leisure-time activities; 8. Outcomes assessment and performance measurement; and
9. Continuous quality improvement programs.6,7 In Ontario, CR is considered the standard of care
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for patients who suffer from or whom have experienced a cardiac-related event.8 For these patients,
CR plays a critical role in the reduction and control of CVD risk factors.6 The scientific literature
almost universally supports the effectiveness of CR programs based on well-established evidence
of reduced morbidity and mortality, healthcare utilization, and increased quality of life.9 Based on
current clinical guidelines, referral to CR is considered standard of care and part of necessary
comprehensive care for individuals after the diagnoses of cardiovascular disease (CVD) or a
cardiovascular event.10,11
A substantial number of studies have reported on the efficacy of exercise-based CR
programs to improve quality of life, to reduce the risk of reinfarction, and to reduce the risk of
cardiac and all-cause mortality (the latter by 20-50%).4 Not surprisingly, CR also results in
improved exercise capacity,12 which will be discussed in more detail later in this chapter.
Additionally, cardiovascular disease risk factors such as cholesterol, blood pressure, insulin
sensitivity, and excess body weight are also improved by CR.4 In addition to individual-level
benefits, the cost-effectiveness of the program provides promising population-level benefit,
including but not limited to a reduction in all hospital admissions.13
Unfortunately, despite the overwhelming evidence to support the cost-effective benefit of
CR, referral, enrollment, participation, and completion of CR in Canada remain discouragingly
low due to both system and patient-level barriers. In Canada approximately one-third of eligible
patients participate in CR.7 Within Ontario, only 22% of eligible patients enroll into CR.7

1.2.

System-level Barriers to Optimizing Patient Outcomes in Cardiac
Rehabilitation

Although patient-level barriers to CR are the focus of this thesis, understanding system-level
barriers to participation and completion of CR provides general insight on population-level
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burdens related to CR. Studies have reported insufficient program capacity for eligible patients
regionally and nationally across Canada. A 2011 analysis of CR capacity in Ontario concluded
that program availability was only 34%, meaning that 35,000 patients annually were unable to
access care because of system-level limits on service availability.14 As of 2018, 182 programs were
active nationally, 72 programs in Ontario, 17 in Quebec, 93 found across the remaining provinces,
and no CR programs currently exist within the three territories.15 The discrepancy in program
availability across Canada is reported to be potentially due to differences in provincial
reimbursement policies.16 For example, CR services provided in Ontario are to the discretion of
hospital budgets17 in comparison to Quebec where patients are expected to cover CR expenses
through their individualized insurance coverages.16 Tran et al. has also reported inadequate
geographic distribution of available programs. A substantial majority of these programs were
situated in either an urban or suburban regions, thus disproportionally reflecting the need of CR
across urban and rural populations.15 Additionally, a substantial majority of programs did not have
another CR program within a 20-kilometer radius.15 This large distance may result in an
inconvenience for those who do not live near a CR program to participate and complete CR.15
Referral and enrollment to CR for eligible patients have also been reported to be substantially low,
being 34%18 and 20%19, respectively.

1.3.

Patient-level Barriers to Optimizing Patient Outcomes in Cardiac
Rehabilitation

In addition to these system-level barriers, there are important patient factors that contribute to suboptimal patient outcomes in CR. Patient outcomes are defined as CR enrollment, participation,
completion, and achievement of clinical targets. Sociodemographic and socioenvironmental
characteristics are examples of individual level-factors that are associated with these outcomes.7,20
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For example, due to inadequate government funding, a proportion of CR patients are expected to
pay the remaining of what is not covered by the Ontario Health Insurance Plan (OHIP), with low
income patients being largely affected.14 As a consequence, patients residing in low-income status
neighborhoods are significantly less likely to complete CR compared to those with high-income.21
There is also evidence that women are less likely to be referred22, enrolled23, and complete CR
compared to men.24,25
In addition to these patient-level factors, there has been an increased awareness of the
influence of patient mental health factors on patient outcomes in CR. Current research has explored
the role of depression with regards to sex, age, cardiovascular diagnosis, and CR referral/entry,
and patient outcomes in a CR program.26,27 Anxiety has also been a mental health factor of interest
with its relationship between CR clinical outcomes. These relationships have been the focus of
research to date and will be discussed in more detail within this chapter. More recently, anxiety
sensitivity (AnxS), defined as a learned cognitive trait that predisposes people to fearful
interpretations of inner processes and events28, has been investigated for its relationships to both
depression and anxiety and for its potential role in influencing patient outcomes in CR.

1.4.

Depression and Anxiety as Barriers to Participation in Cardiac
Rehabilitation

Much of the literature supports both depression and anxiety as barriers to optimal patient
outcomes in CR. Understanding relationships between depression, anxiety, and CR will
demonstrate the need to investigate a similar, yet conceptually different construct, AnxS.
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1.4.1. Depression in Patients Participating in Cardiac Rehabilitation
Depression, a range of mood disorders, is both a medical and mental health illness that negatively
impacts the way affected individuals think, feel, and act on a day-to-day basis.29 “Depression” is
an umbrella term used to characterize conditions ranging from self-reported depressive symptoms
and depressive episodes, to clinical diagnoses such as Major Depressive Disorder (MDD) or
Persistent Depressive Disorder (PDD), among many others, that can and do affect people
differently at different times.
There is an enormous literature on the association between CVD and depression.
Studies report that about 40% of patients who have suffered a major cardiac-related event have
also been diagnosed with MDD.30 Multiple studies have reported that depression can both worsen
the prognosis for multiple CVDs and can also increase the risk of myocardial infarction (MI), and
stroke.31–34 A recent 2021 review reported that individuals surviving an acute MI have significantly
lower levels of depression compared to individuals not surviving. Hopelessness, a dimension of
depression, has been reported to predict all-cause mortality in patients with coronary heart failure
(CHF). Consistent with these findings, studies have reported depression to be a reliable predictor
for CVD.35,36 On the reverse side, there is also evidence that CVD may also cause depression.37
Given the strong association between depression and CVD, it is expected that depression impacts
patient outcomes in CR. Depressed CR patients are significantly less likely to complete CR.26 In
addition, gender differences are seen as women report higher levels of depressive symptoms
compared to men at baseline of CR.38 As a response to this issue, evidence-based guidelines for
CR have been restructured, recommending that patients be routinely screened for depression due
to its high prevalence among those with CVD.39
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1.4.2. Anxiety in Patients Participating in Cardiac Rehabilitation
Anxiety disorders are a group of mental health disorders characterized by frequent, intense,
excessive fear and worry, and are responses that are substantially different in intensity and
frequency to “normal” stress responses to common, everyday events.40 Like depression, anxiety is
an umbrella term used to characterize a spectrum of conditions ranging from self-reported
symptoms of anxiety to clinical diagnoses such as Generalized Anxiety Disorder (GAD) and Social
Anxiety Disorder (SAD), among many others. Compared to depression there has been less
investigation of associations between anxiety and CVD. Nonetheless, anxiety has also been
reported to be significantly associated with CVD risk factors such as hypertension, specific types
of CVD such as CAD, heart failure, and an overall increased risk of CVD mortality.41–44 For
example, 20-30% of patients who have experienced acute coronary syndrome have reported
elevated levels of anxiety.45,46 Individuals exhibiting higher baseline symptoms of anxiety have
demonstrated a lower likelihood of completing CR, particularly at the early stages of the
program.39 Similar to depression, women report higher levels of anxiety compared to men at
baseline of CR.38 Evidence-based guidelines for CR have also been modified to routinely screen
for anxiety also due to its high prevalence among those with CVD.39

1.5.

Anxiety Sensitivity

This section will aim to define AnxS, discuss distinctions from and relationship to depression and
anxiety, and explore what is currently known about the relationship between AnxS and CVD,
exercise, and CR.
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1.5.1. Defining Anxiety Sensitivity
AnxS is defined as a learned cognitive trait that predisposes people to fearful interpretations of
inner processes and events28 and is conceptually distinct from anxiety.47 Whereas anxiety is
defined as the anticipation of future threat48, AnxS is defined as interpretating physiological
responses elicited by anxiety as threatening.28 For example, an individual with high AnxS who
experiences an elevated heart rate after an exercise session, is much more likely than someone with
low AnxS to respond to the elevated heart rate with excessive fear that they are experiencing a
heart attack. In the context of the current investigation, AnxS is important to understand because
of demonstrated and potential associations with other mental health factors, cardiovascular health
outcomes, and exercise, which have been extensively investigated in CR. AnxS has also been
evidenced to be targeted for treatment with interventions like cognitive restructuring,
psychoeducation, interoceptive exposure, and other cognitive behavioural therapy (CBT) styled
approaches.49 However, the role and potential influence of AnxS has been understudied in CR.

1.5.2. Measuring Anxiety Sensitivity
The measurement of AnxS has evolved over the past two decades, as the construct itself has
become more precise and the understanding of its component factors has improved. The Anxiety
Sensitivity Index (ASI original) was developed in 1986. The original ASI consisted of 16 items,
each item being scored from 1 to 4, with total scores ranging from 0 to 64. Later investigation
provided evidence that AnxS could be divided into 3 factors: fear of (1) physical symptoms; (2)
publicly observable anxiety symptoms; and (3) cognitive dyscontrol.50,51
In 1998, the Anxiety Sensitivity Index-Revised (ASI-R), consisting of an extensive
36 items, was developed to prove that AnxS could be divided into multiple factors. Taylor and
Cox (1998) added a fourth dimension within the AnxS construct: (1) fear of respiratory symptoms;
7

(2) fear of publicly observable anxiety reactions; (3) fear of cardiovascular symptoms; and (4) fear
of cognitive dysfunction.51 The validity of the ASI-R was later demonstrated in several studies,
one of which was by Deacon et al. (2003), where they used two non-clinical samples to investigate
their hypothesis of AnxS having a structure comprised of four dimensions. Although this study
provided evidence that the ASI-R was more valid and reliable compared to the original ASI,
several items on the ASI-R reported both the fear of a sensation and the belief that sensations result
in danger, making the definition of AnxS unclear.52
Taylor and Cox (1998) also developed the Anxiety Sensitivity Profile (ASP) which
added two extra dimensions to the ASI-R: fear of (5) gastrointestinal symptoms; and (6) fear of
dissociative and neurological symptoms.51,52 This was an attempt to assess additional domains that
the ASI-R could examine but was not used as much compared to the other AnxS indexes due to
its length of 60 items. Taylor et al. (2007) then developed the Anxiety Sensitivity Index-3 (ASI3), which is a more stable and multidimensional tool used to assess AnxS in both clinical and nonclinical samples and has also demonstrated greater validity and reliability in comparison to the
previously designed measures.52,53 With a total of 18 items, each item of the ASI-3 is also scored
from 1-4, with the total score ranging from 0 to 72.54

1.5.3. Relationships between Anxiety Sensitivity, Depression, and Anxiety
The literature has established AnxS as a distinct construct that can be independently targeted for
treatment.28 AnxS is also known to be related to anxiety and mood disorders. AnxS is predictive
of developing a wide range of anxiety related disorders55,56, as individuals with high AnxS are
more likely to develop an anxiety related disorder compared to those with low AnxS.52,56–58 Studies
examining the association between AnxS and depression have generally reported an association,
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though more modest than the association between AnxS and anxiety disorders. Olatunji and
Wolitzky-Taylor (2009) meta-analysis investigated differences in AnxS between individuals with
anxiety disorders, depressive disorders, and healthy individuals. Results suggested that
participants in the anxiety group reported higher AnxS scores compared to those in the mood
disorder group. Naragon-Gainey (2010) conducted a similar meta-analysis to investigate the
relationship between AnxS, depressive disorders, and anxiety disorders. Results supported strong
relationships between AnxS with each of depression, generalized anxiety disorder (GAD), and
posttraumatic stress disorder (PTSD). Additionally, AnxS was more closely associated to distress
disorders, such as depression, GAD and PTSD, compared to fear disorders, such as panic,
agoraphobia, social anxiety disorder, and specific phobias.56 While depression, anxiety, and AnxS
are similar, they are distinct from each other, each are measured separately, and each are addressed
differently in a clinical setting. Therefore, there is a need to better understand the role of AnxS and
its relationship to depression, anxiety, and cardiovascular disease symptomology, along with CR
adherence and completion in patients enrolled in CR programs.

1.6.

Anxiety Sensitivity and its Potential Impact in Cardiac Rehabilitation

1.6.1. Anxiety Sensitivity and Cardiovascular Disease Risk Factors Targeted
During Cardiac Rehabilitation
A variety of studies have explored the association between AnxS and the traditional CVD risk
factors, indicators of pre-clinical CVD, and CVD symptoms. For example, Farris and Abrantes
(2017) demonstrated that smokers with CVD report significantly higher AnxS compared to
smokers without any cardiovascular health implication.59 The importance of this is key as smoking
cessation is an important clinical outcome in CR.
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Hypertension has been historically noted as a risk factor for CVD, with literature starting
to report its association with AnxS. Studies suggest that individuals with mild to moderate
hypertension reported significantly higher AnxS compared to those with normal BP.60,61 Those
with mild to moderate hypertension did not report significantly more anxiety compared to
individuals with normal BP60, providing further evidence of a conceptual difference between AnxS
and anxiety. One study suggests that non-compliance to hypertensive medication may be
attributable to misinterpretation of normal medication side effects.62 Alcántara et al. (2014)
reported that nearly double the patients with high AnxS were non-adherent to their BP medication
compared to those with low AnxS. They concluded that patients with high AnxS were more likely
to misinterpret their bodily sensations as threatening when they took their BP medication, which
made them more likely to avoid taking it as prescribed.
In addition to hypertension, AnxS has been evidenced to be associated with other risk
factors for CVD. Seldenrijk et al. (2013) suggests that individuals with significantly higher AnxS
demonstrated a significantly increased likelihood of the presence of carotid plaque and increased
arterial stiffness, even in healthy patients. Interestingly, depression and anxiety partially mediated
the association between AnxS and increased stiffness.63 Investigation of anxiety and/or depression
potentially mediating associations between AnxS and patient outcomes assessed in CR is currently
understudied and merits further investigation.
In addition to CVD risk factors, studies have reported associations between AnxS and
higher levels of self-reported symptoms in patients with CVD. Ong et al. (2006) reported that
individuals with high AnxS reported significantly greater atrial fibrillation (AF) symptom severity.
Additionally, Chiaie et al. (1996) reported that AnxS was significantly higher in patients with
mitral valve prolapse compared to healthy individuals.64
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There is emerging evidence that AnxS is associated with CVD risk factors. More research
is needed to explore whether AnxS can serve as an independent risk factor for incident CVD and
whether mitigating AnxS in patients with CVD might improve patient outcomes in CR.

1.6.2. Anxiety Sensitivity and Exercise, a Critical Component of Cardiac
Rehabilitation
Exercise is a key and central component of CR, therefore, understanding what is known about
AnxS and exercise is important. This section will discuss the associations between AnxS and
exercise and discuss the impact exercise has on AnxS.

1.6.2.1.

Associations Between Anxiety Sensitivity and Exercise

The literature suggests AnxS to be significantly associated with both physical activity and exercise.
Studies report that individuals with high AnxS engage in significantly less physical activity than
individuals with low AnxS.65 More specific to aerobic exercise, Hearon and Harrison (2020)
hypothesized that AnxS would be associated with greater sedentary time. Contrary to their
hypothesis, AnxS was not a significant predictor for sedentary time, but higher AnxS was
associated with less aerobic exercise.66 Moshier et al. (2013) also reported that individuals with
low AnxS engage in significantly more vigorous exercise compared to individuals with high
AnxS.67 Interestingly, the association was not significant when gender/sex was added to the model;
the effect of sex on this association will be discussed later in this section. Studies also suggest that
AnxS is significantly predictive of exercise behaviour, indicating that individuals with high AnxS
at baseline are significantly less likely to improve their exercise behaviour after one week.68 AnxS
was also able to predict change in cardiorespiratory fitness measured as peak metabolic equivalents
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(MET; 1 MET = 3.5 ml O2 / kg body wt / min) achieved on an exercise stress test.68 A review by
Horenstein, Potter, and Heimburg also addressed this association they investigated AnxS as a
possible risk factor for chronic medical conditions. They speculate that avoidance of exercise by
individuals with high AnxS may be due to fear of physiological sensations (e.g., increased heart
rate) accompanying physiological arousal caused by exercise.69
With clear evidence of AnxS being associated with exercise, a few studies evaluated the
impact of gender in this relationship. McWilliams and Asmundson reported significant
associations between exercise and AnxS among men but not women, suggesting that only men
with high AnxS reported less physical activity.70 DeWolfe et al. (2020) conducted a study to
specifically investigate the gender differences in physical activity, and to determine whether this
relationship was mediated by AnxS. Their findings suggest that women engaged in significantly
less physical activity compared to men and AnxS partly mediated the relationship between gender
and physical activity.71
As stated previously, research suggests that body weight may play a moderating role in the
AnxS and exercise interaction. Hearon et al. (2014) reported that AnxS, body mass index (BMI),
and their interaction, were predictors for duration engaged in physical activity. Obese individuals
with high AnxS engaged in less physical activity compared to obese individuals with low AnxS.72
Smits et al. (2010) reported findings consistent with Hearon et al. (2014), where an interaction
was found between AnxS, exercise and BMI. Additionally, they reported that fear of exercise was
significantly greater in individuals with high BMI and high AnxS.73
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1.6.2.2.

The Impact of Exercise on Anxiety Sensitivity

Despite the sub-optimal exercise outcomes in individuals with high AnxS, individuals able to
participate in exercise have demonstrated significant reductions in AnxS. Many studies assessing
the impact of exercise on AnxS were done using sample sizes of young adults, hence, the
implications of these studies in relation to CR are uncertain. As previous studies mentioned have
reported associations between AnxS and tolerance of exercise, studies have reported that
individuals engaging in a single session of aerobic exercise we able to reduce their AnxS
significantly more than those who do did not engage in exercise at all.74–76 Broman-Fulks et al.
(2004) investigated the effects of high vs. low intensity aerobic exercise-induced physiological
arousal on AnxS. Significant reductions in AnxS were observed in the high intensity exercise
group, with reduction maintained after a 1-week follow-up.77 In comparison, the low intensity
exercise group did not demonstrate a significant reduction in AnxS up until 1-week follow-up.
Consistent with Broman-Fulks hypotheses, a reduction in AnxS after engaging in just low intensity
exercise is promising, supporting the impact of exercise on clinically relevant psychological
factors.
There is also evidence that gender may moderate the impact that exercise has on AnxS, as
men have shown a significantly larger reduction in AnxS during exercise treatment compared to
women.78 Interestingly, Medina et al. also observed no significant difference between genders.
They speculate the physiological response to exercise could be responsible for the mid-treatment
difference found between sexes. Sabourin et al. (2011) investigated barriers to exercise in women
with high AnxS. Results suggested that compared to individuals with low AnxS, individuals with
high AnxS perceived more barriers and benefits to exercise.79 Notably, they also demonstrated that
individuals who perceived more barriers than benefits to exercise reported significantly lower
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fitness scores compared to individuals who perceived more benefits to barriers.79 This may elicit
clinical complications for treating anxiety-related disorders among high AnxS individuals who
perceive more barriers than benefits to exercise.
Zvolensky et al. observed that individuals who engaged in exercise did not only
significantly reduce their AnxS, but also demonstrated abstinence from smoking compared to
individuals who did not exercise.80 As previously mentioned, the importance of this finding is key
as smoking cessation is a patient outcome assessed in CR. Additional studies comment on
relationships between AnxS, smoking, and exercise, but that analysis is beyond the scope of this
thesis.
Studies have also evaluated the effectiveness of CBT combined with exercise. Sabourin et
al. (2016) reported reductions of AnxS in individuals who engaged in a combined CBT and
exercise treatment compared to individuals who were educated on the importance of exercise,
nutrition, and sleep81, although this study was done exclusively with women. Consistent with
findings reported by Sabourin, Smits et al. (2008) reported that AnxS was reduced significantly
post-treatment and at follow-up evaluations of a combined CBT and exercise treatment.
Additionally, AnxS mediated the relationship between both depression and anxiety with exercise
with mediation being stronger among individuals with high AnxS.82 As previously mentioned,
depression and anxiety are routinely assessed in CR, so this finding may provide clinical
implications.
Reported reductions in AnxS using exercise, CBT, or both is promising as it supports the
feasibility and effectiveness of potentially targeting AnxS.
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1.6.3. Anxiety Sensitivity and Cardiac Rehabilitation
To date, only two studies have investigated AnxS in CR. Farris et al. (2018) explored the
association between AnxS and fear related to negative consequences of exercise in CR
participants. On average, patients reported a moderate level of AnxS, yet of those patients, nearly
one-third of them reported high AnxS.83 Further analysis deemed AnxS to be associated with fear
of exercise, with patients being more likely to drop out of either centre-based or home-based
programs. In a more recent study by Kraemer et al., analysis was done to examine the effects of
each dimension of AnxS (physical, cognitive, and social) on exercise tolerance. Opposed to the
previous study, this investigation focused on patients enrolled in a cardiopulmonary rehabilitation
program. Consistent with previous studies, it was reported that increased levels the physical
dimension of AnxS were associated with low exercise tolerance.84 Kraemer et al. speculate that
individuals with cardiopulmonary conditions reporting high AnxS may experience distress when
exertion-related symptoms (i.e. elevated heart rate) are stimulated in patients, subsequently
resulting in exercise avoidance. Given the limited literature on the direct role of AnxS in CR, this
area of research merits further investigation.

1.7.

Summarizing and Synthesizing Existing Literature: What is known
and Knowledge Gaps about the Role of Anxiety Sensitivity in Cardiac
Rehabilitation

To date there has been very little investigation of AnxS in relation to CR patient outcomes. Current
evidence demonstrates that AnxS is significantly related to anxiety, yet more moderately related
to depression. As depression and anxiety are important influencers of deleterious CR outcomes,
understanding the concurrent relationships among AnxS, depression, and anxiety within CR may
have important clinical implications. Key existing literature that evaluates AnxS and its
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associations with a variety of patient outcomes has also been highlighted. Though limited, a few
studies have indicated that increased AnxS is associated with hypertension, heart disease, and other
CVD risk factors. Further investigation is needed to understand what the relationship is between
AnxS and changes of these variables in individuals participating in CR. Importantly, studies with
exercise have reported that individuals with high AnxS engage in less physical activity compared
to individuals with low to moderate AnxS. More promising results, however, have indicated that
even participating in just one 30-minute session of exercise may significantly reduce AnxS. It is
important to understand the relationship between AnxS and exercise as it and physical activity are
fundamental components of CR. Psychological treatment has also been reported to decrease AnxS
both independently and in combination with exercise, which indicates a potential target for
treatment. By investigating the relationships between AnxS and these factors within the scope of
CR, possible mitigation interventions can be designed to increase CR participation and achieve
appropriate risk factor targets in CR. As stated earlier in this chapter, much of the current literature
focuses on a much younger population. This thesis will study a CR population by collecting and
analyzing data from patients enrolled in a CR program in London, Ontario.
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Chapter 2
2.0.

Rationale

It has been firmly established that CR is both efficacious and cost-effective, yet participation in
and completion of CR remain alarmingly low across Ontario. Anxiety, and especially depression,
are important barriers to patient completion of CR. In addition to depression and anxiety,
understanding the importance of AnxS and how it may mediate or moderate the impact of
depression and anxiety on CR outcomes is advancing.
The novelty of this thesis is in prospectively investigating whether AnxS influences
patient outcomes in CR, as targeting AnxS for treatment may provide clinical therapeutic benefit.
Evidence demonstrates that while anxiety and depression are associated with worse CR outcomes,
AnxS is associated with each of these, and compared to them, may be a modifiable psychological
factor to target for treatment.28 Therefore, the overall research problem of this thesis is to
investigate whether AnxS is associated with patient outcomes in cardiac rehabilitation.

2.1.

General Hypothesis

We hypothesized that individuals with high anxiety sensitivity enrolled in cardiac rehabilitation
will have sub-optimal clinical outcomes from their participation in a cardiac rehabilitation
program.

17

2.2.

Using a One Health Approach to Address the Research Question

2.2.1. What is One Health and What is a One Health Approach
The term One Health was first used following the occurrence of the severe acute respiratory
syndrome (SARS) virus and avian influenza H5N1, when the link between animal and human
health started to become recognized as threatening.85 According to the Centers for Disease Control
and Prevention (CDC), One Health is defined as a “collaborative, multisectoral, and
transdisciplinary approach — working at the local, regional, national, and global levels — with
the goal of achieving optimal health outcomes recognizing the interconnection between people,
animals, plants, and their shared environment.”86 The CDC adds that “One Health is an approach
that recognizes that the health of people is closely connected to the health of animals and our
shared environment. One Health is not new, but it has become more important in recent years. This
is because many factors have changed interactions between people, animals, plants, and our
environment.” Stakeholder involvement is a fundamental way to facilitate collaboration both
within and across multiple sectors at the local, regional, national, and global levels. Khan et al.
(2018) evaluated the functioning of collaboration of stakeholders within and between One Health
networks in Africa, Asia, and Europe. Their results suggest the need and importance of increasing
collaborations across sectors and paying more attention to the environmental health aspect of the
approach.87 The Public Health Agency of Canada (PHAC) has also highlighted disease
surveillance, response, and prevention as key features that make up One Health.88
Historically, zoonotic disease, vector-borne disease (i.e. rift valley fever)89, and additional
communicable disease complications have benefitted from using a One Health approach to resolve
health issues. However, there is growing recognition of the need to extend this approach to chronic
diseases.86
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2.2.2. The Application of the One Health Approach to Address the Research
Question
Addressing the research question using the One Health approach was done by: 1. Applying the
PHAC version of the health problem in CR, addressing human, animal, and environmental aspects
of One Health; and 2. Engagement of multisectoral stakeholders along the continuum of
prevention, detection, and treatment to develop and implement realistic solutions that optimize the
health and well-being of participants enrolled in CR.
Human health is one of the core pillars within the One Health framework that may have
clinical implications in CR. As previously mentioned in Chapter 1, the prevalence of people living
with CVD has increased, subsequently increasing the associated burden on society.3 To evaluate
the influence of this pillar, relationships between AnxS and CVD risk factors in CR were
investigated.
To address the environmental pillar of One Health, the influence of social environmental
factors on AnxS was investigated. Amid the COVID-19 pandemic, individuals across the globe
have been faced with prolonged social isolation due to extensive social distancing measures.90,91
Arguably, older individuals have been impacted the most by set social distancing guidelines, with
many self-reporting loneliness.90,91 In a cross-sectional study exploring adverse outcomes
associated with loneliness, high self-reported loneliness was associated with greater depression
and anxiety.92,93 Loneliness was also associated with increased CVD93, implying an interaction
between the social environmental and human health pillar. Social environmental factors, such as
marital status, and its impact on AnxS were investigated. Though exploring the influence of
COVID-19 in CR was beyond the scope of this thesis, it played a huge part of the context within
this thesis.
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Although animal health was not directly investigated in this thesis, translational animal
models have also played a significant role when investigating CVD and its associated adverse
outcomes. Research with small animals such as mice and rabbits have been advantageous and are
continuously used to advance our knowledge on the progression and mechanisms associated with
CVD.94 CVD translational research has supported the importance of and clear need to mitigate
adverse cardiac outcomes experienced by individuals through CR. This is yet another example of
the interconnection between the human and animal health pillars in the One Health approach.
Collaboration among transdisciplinary stakeholders play a critical role in preventing,
detecting, and mitigating adverse health outcomes.85,86 There is currently a gap in knowledge
dissemination and implementation strategies when clinically relevant publications are produced.95
Bridging this gap through stakeholders is a key component of the One Health approach. In this
thesis, identified stakeholders who can contribute to reducing the burden associated with AnxS,
depression, and anxiety may have clinical implications in CR. The use of stakeholders has proven
to be effective when mitigating adverse outcomes associated with infectious diseases.85
To fully investigate the clinical implications of AnxS in CR and to formulate possible
mitigation strategies, a One Health approach was employed in this thesis.

2.3.

Aims and Hypotheses (Revised)

Specific Aim 1: To investigate the associations between anxiety sensitivity and sociodemographic,
socio-environmental, and clinical characteristics at initial assessment of CR enrollment.
Hypothesis 1a: Females will have higher levels of anxiety sensitivity compared to males.
Hypothesis 1b: Individuals with partners will have lower levels of anxiety sensitivity
compared to individuals without partners.
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Hypothesis 1c: Individuals with higher levels of anxiety sensitivity will have less
favourable clinical characteristics.

Specific Aim 2: To investigate interrelationships between anxiety sensitivity, symptoms of
anxiety, and symptoms of depression, and how these are associated with CVD risk factor
characteristics at initial assessment of CR enrollment.
Hypothesis 2: Individuals with higher levels of anxiety sensitivity combined with higher
symptoms of anxiety and/or depression will have less favourable CVD risk factor
characteristics.

Specific Aim 3: To determine if anxiety sensitivity at initial assessment predicts change in
physical activity, exercise capacity, and diet at 6-week follow-up.
Hypothesis 3: Individuals with higher levels of anxiety sensitivity will have smaller
improvements in physical activity, exercise capacity, and diet after 6-week follow-up.

Specific Aim 4: To identify key stakeholders within different disciplines who have the power,
influence, and potential to assist in investigating, preventing, and mitigating the burden associated
with anxiety sensitivity in CR.
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Chapter 3
3.0.

Materials and Methods

In this chapter, Section 3.1 through Section 3.7 will explain the methods used to address aims 13, while section 3.8 through to the end of the chapter will intend to address aim 4.

3.1.

Study Design

This study used an observational, prospective, longitudinal cohort design for patients referred to
and participating in the Cardiac Rehabilitation and Secondary Prevention Program at St. Joseph’s
Health Care London. The sample consisted of consecutively consenting patients. Approval was
obtained by the Health Sciences Research Ethics Board (HSREB) at Western University and the
Lawson Health Research Institute in London, Ontario. Copies of both approval letters can be seen
in Appendix A of this thesis. In response to the Provincial state-of-emergency and Guidance from
Provincial (CorHealth Ontario)96 and National (Canadian Cardiovascular Society)
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bodies, the

St. Joseph’s CR program shifted to virtual delivery of CR programing in the spring of 2020 which
continued throughout the summer of 2020 (see Appendix B for detailed flow diagram).

3.2.

CR Program for Patients in this Study

Due to the COVID-19 pandemic, CR programming was completed on a virtual basis. This was the
mode of delivery for all patients going through CR in this study. Virtual CR programming
comprised of multi-disciplinary interventions to optimize patients’ physical activity, exercise,
nutrition, anxiety, depression, and pharmacotherapy risk profiles.12 As restrictions eased in the fall
of 2020, virtual programming continued, with some cardiopulmonary exercise test (CPET)
assessments resuming as necessary for appropriate clinical care. CPET assessments included

22

evaluation of resting and peak measures of heart rate and blood pressure (systolic and diastolic),
as well as metabolic assessments such as VO2 peak.

3.3.

Study Outcomes

There is one primary outcome for the revised study, as follows:
1. Primary:
a.

Changes, and/or improvement in clinical characteristics for patients enrolled in the
cardiac rehabilitation and secondary prevention program.

b. Achievement of clinical/therapeutic outcomes for patients enrolled in the cardiac
rehabilitation and secondary prevention program. Note, because most patients in
this study have only completed initial assessment, achievement of these targets
cannot be evaluated at this time.

Definition of Primary Outcomes
Per evidence-based clinical care guidelines and standards defined for CR in Canada98, there are 7
therapeutic outcomes defined for patients. A description of these therapeutic goals and a brief
overview of how we will be quantifying and measuring these goals in this study is included below1:
(1) Physical activity: Cumulative minutes – By the time of discharge, patients would be
expected to achieve a total of 150 minutes of physical activity each week.98 Minutes of
physical activity will be measured via the Godin Leisure-Time Questionnaire (GODIN), a
validated self-reported questionnaire that consists of 4 questions.99 The first 3 questions are
scored based on frequency of vigorous, moderate, or mild engagement of physical activity

1

A complete copy of each self-reported tool is included in Appendix C of this document.
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for at least 15 minutes in the past week, multiplied by 9, 6, and 3, respectively and then
totally.100 Scores were than categorized into active (24 points or more), moderately active
(14 to 23 points), or sedentary (less than 14 points).100 Godin and Sheppard reported strong
reliability of this assessment tool by assessing leisure-time physical activity across different
populations, different countries, and different seasons.100 The tool has also been
successfully validated to be correlated with percentile VO2 max and percentile body mass,
which are two determinants of physical fitness, with p-values of <0.001 and <0.01,
respectively.
(2) Exercise: Exercise capacity – the therapeutic goal is to achieve a 0.5 MET increase from
baseline to discharge.98 A MET is defined as a unit expressing rate of oxygen consumption
while performing a specific activity. This was approximated using the Duke Activity Status
Index (DASI), which is a reliable and validated self-reported questionnaire consisting of
12 questions.101 The total DASI score ranged from 0 to 58.2 points.102 Raw DASI scores
were then converted to METs to estimate peak rate of oxygen intake. Hlatky reported a
significant spearman correlation (0.80) between DASI scores and peak oxygen intake,
supporting its validity in estimating METs.101 Scores were than categorized into poor (1-4
METs), moderate (4-7 METs), good (7-10 METs), or excellent (over 10 METs) level of
METs achieved.103
(3) Diet – the therapeutic goal for all patients who enter CR is to be offered clinical support
and education on making dietary changes consistent with the Mediterranean Diet.98 In this
study, dietary status was assessed using the Mediterranean Diet Questionnaire (MDQ),
which is a reliable, validated self-reported questionnaire consisting of 14 questions.104–106
Each question was given a score of either 0 or 1, with total score ranging from 0 to 14.
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Scores were then categorized into low (score of 5 or less), moderate (score between 6 to
9), or high (score of 10 or more) levels of adherence to the Mediterranean diet.104
(4) Blood pressure – the specific therapeutic target for blood pressure is tailored to each patient
based on a complex algorithm as established by the Hypertension Canada Guidelines.98,107
The general target for each patient is 140/90 mmHg. The resting diastolic and systolic
blood pressures were categorized as within target (<90mmHg/<140mmHg) or at risk
(>90mmHg/>140mmHg). All measurements were abstracted from the patient’s health
record.107
(5) Blood lipids – the therapeutic goal was a low density lipoprotein (LDL-c) reduction of 50%
or a level of <2 mmol/L.98 Non-high-density lipoproteins (non-HDL-c) were assessed in
this study and categorized as within target (<2.6mmol/L) or at risk (>2.6mmol/L). All
measurements were abstracted from the patient’s health record.108
(6) Glucometabolic control – this was determined by the level of hemoglobin A1c (HbA1c) as
recommended by the Canadian Diabetes Association guidelines98,109, HbA1c was
categorized as meeting target (<7.0%) or at risk (>7.0%).110 All HbA1c measurements were
abstracted from the patient’s health record.

3.4.

Study Predictor Variables (Independent Variables)

Key objectives for this study were to better understand AnxS, how it may impact outcomes from
CR, and how it may interrelate with anxiety and depression to impact outcomes from CR. For this
study, these key constructs (independent variables) were measured as follows:

(1) Anxiety Sensitivity: This was measured using ASI-3, which is a reliable and validated
questionnaire, compared to earlier versions of the tool, comprised of 18 questions (see
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Section 1.5.2.).52,53 An internal consistency test reported the reliability of each of the 3
subscales within the questionnaire with Cronbach consistency scores above 0.70. Factorial
validity was confirmed across six replication samples in both clinical and non-clinical
populations.53 Each question was scored from 1 to 4, with total scores ranging from 0-72.
Scores were categorized into high (greater than 22 points), moderate-to-high (17-22
points), or low (less than 17 points) levels of AnxS.111

(2) Symptoms of Anxiety: This was measured using the Patient Health Questionnaire-4 (PHQ4), which is a reliable, validated questionnaire which has been routinely used as part of
standard of care in CR.112 Further, the PHQ-4 has been reported to be sensitive for detecting
change in health status across a 3-month timespan.113 The PHQ-4 is comprised of 4
questions, 2 of those questions specifically address anxiety. Each of the questions were
scored from 0-3, resulting in a total possible score of 6. A clinical cut off score of 3 was
used to identify an individual exhibiting high levels of anxiety.114

(3) Symptoms of Depression: This was measured using the Patient Health Questionnaire-4
(PHQ-4), with the remaining 2 questions specifically addressing depression.112 Scoring and
clinical cut off scores for symptoms of depression are identical to symptoms of anxiety on
the PHQ-4 as mentioned above.

3.4.1. Covariates
Additional variables (covariates), including information regarding age, patient demographics, and
clinical characteristics, were necessary to understand key relationships between the predictor
variables (AnxS, anxiety, and depression) and study outcomes (defined above) to address the
research question using the One Health approach. All necessary sociodemographic (biological
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sex), socio-environmental (marital status), and clinical characteristics (adherence to Mediterranean
diet, resting blood pressures, blood lipid, and blood glucose) were abstracted from the patient’s
medical record, maintained by the CR Program at St. Joseph’s Health Care London.

3.5.

Participant Enrollment and Consent

A complete overview of the patient referral, study screening, consenting process, and the data
collection process is included in the study flow diagram (See Figure 1 of Appendix B).
Patients are referred to the CR Program at St. Joseph’s Health Care London, by a physician
(family practitioner, cardiologist, or another specialist). Upon receipt of this referral, the clinical
team at the CR Program at St. Joseph’s Health Care London mails each referred patient a
comprehensive information packet including information about their CR intake appointment, as
well as a general research pamphlet (UWO REB approved) informing them that they may be
contacted for interest in taking part in research activities within the CR Program at St. Joseph’s
Health Care London; this pamphlet allows for the research staff to directly contact patients if the
patients do not opt-out from being contacted (refer to Figure 1 in Appendix B for the opt-out
process). Patients indicating that they did not want to learn more about the study or that they were
not interested in participating, were not contacted further. Patients not indicating any of the
previously mentioned were then screened by the research team for eligibility in the study. Patients
were eligible to join if it was their first time enrolling in a CR program. Patients were considered
ineligible if they were unable to complete the verbal informed consent unaided and/or enrolled in
the Atrial Fibrillation Navigator study, the latter being because they were or could have been
enrolled in related research.
Patients not indicating that they were not interested in participating were then contacted by
the research team to: (1) determine method of sending the letter of information to the patient, and
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(2) schedule a follow-up appointment at a time of their convenience, to review the letter of
information and complete verbal informed consent. Patients were then sent a copy of the
documented consent via mail or email per patient preference. (See Figure 1 in Appendix B). Once
consent was received, the patient was then successfully enrolled into the study.

3.6.

Study Procedures

For this study, procedures included completion of self-reported questionnaires by participants and
abstraction of data from the electronic medical record for CR Program at St. Joseph’s Health Care
London. As described in detail below, participants were asked to complete these questionnaires at
initial assessment and at 6-week follow-up points during their 6-month participation in the CR
program. This data was collected between February to July of 2021. Information relating to study
outcomes and covariates were abstracted from the electronic medical record. Information on
medication was not collected or included in this study due to the lack of variation between
participants, making such data not as informative. A summary of the data collection procedures is
included in Table 1 below.
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Table 1: Data Collection Assessment Instruments
Data
Data Category

Data Collection Period
Source

Physical Activity

GODIN

Exercise Capacity

DASI

Diet

MDQ

Initial assessment and 6-week
follow-up

Primary Outcomes
Blood Pressure
(Resting systolic and
diastolic)
Blood Glucose Control
(HbA1c)

PHR

Intake of CR

Blood Lipid Control (nonHDL-c)
Anxiety Sensitivity

ASI-3
Initial assessment and 6-week
follow-up

Depression

Predictor Variables

PHQ-4
Anxiety

Covariates

Age, Patient
Sociodemographic,
Socioenvironmental, and
Clinical Characteristics

PHR

Intake of CR

Abbreviations: GODIN, Godin leisure-time Questionnaire; DASI, Duke Activity Status Index; MDQ, Mediterranean
Diet Questionnaire; PHR, Patient Health Record; ASI-3, Anxiety Sensitivity Index-3, PHQ-4, Patient Health
Questionnaire-4

Questionnaire Administration
Following consent, arrangements were made with each consenting participant regarding the
collection of the self-reported questionnaires. As part of the previously mentioned informed
consent process, participants were given options in which they preferred to complete the
questionnaires. The available options were as follows:
29

a. Phone call – The student researcher will call the participant and go through all questions
on each questionnaire via REDCap. REDCap is a hospital approved web-based data
management system that lets participants directly answer questions. REDCap stores
information following the hospital security guidelines and policies.
b. Videocall – The student researcher will videocall the participant via WebEx, a hospital
approved application, and complete each questionnaire. Data from each questionnaire will
be documented and stored in REDCap.
c. Mail – The student researcher will send a prepaid postage envelope with all questionnaires
enclosed. The participant will be responsible for sending back the envelope with all
questionnaires completed. Once the questionnaires are returned, the student researcher will
replicate the responses into REDCap.
d. Online via REDCap – The student researcher will email the participant a link to REDCap
for them to complete the questionnaires independently online.

Participants were also given an optional reminder one week prior to their next set of questionnaires
– options for reminders included either a phone call, email, or mail out. Participants enrolled in
the study who had not completed questionnaires on their scheduled date were sent up to two
reminder requests over the course of the subsequent three weeks. If they did not complete those
questionnaires, they were not contacted until the next scheduled time point for data collection.

3.7.

Data Management

As previously mentioned, all data completed by participants in this study were confidentially
added into REDCap by either a member of the research team or directly by the participant
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themselves. REDCap was also setup to include a scoring algorithm for each of the self-reported
questionnaires – data abstracted from REDCap included answers to each question and each
participant’s respective score for each questionnaire.

3.8.

Data Analysis

All statistical analyses were performed using SPSS software.115 Descriptive analytic approaches
such as mean, standard deviation, and proportions were used to characterize sociodemographic,
socio-environmental, and clinical characteristics of participants. A test of normality was conducted
for each of the study outcomes using the Shapiro-Wilk Test. Dependent on the outcome of
normality, study outcomes were reported with either means and standard deviations, or median
and 25th/75th percentiles. Due to non-normal results of reported GODIN, DASI, and blood pressure
data using the Shapiro-Wilk test, we exclusively relied on the Chi-Square, a univariate statistical
test, to investigate the relationship between AnxS and the study outcome variables for the
following reasons:
a. Appropriate test to use for non-normality of the tested variables
b. Addresses the challenges of outliers in the small sample size in the study
c. Results are easily interpretable using this test

Although adherence to Mediterranean diet scores, blood lipid, and blood glucose data were
reported as normal, to be consistent with how we evaluated non-normal data, the Chi-Square Test
was used. The use of other statistical tests (i.e., t-tests and regression) will be revisited when a
larger sample size is obtained.
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3.9.

Identifying Key Stakeholders

An element of an approach used by the RECARE project116 was used in this thesis to systematically
identify a diverse range of stakeholders to investigate, prevent, and mitigate the burden associated
with the mental health factors in CR. The first step was to establish identification criteria between
the student researcher and members of research committee. This allowed for a common objective
to be set about the purpose of each stakeholder and their potential engagement in their project.116
Identification criteria established for this was to incorporate multidisciplinary stakeholders, as
characterized by the One Health definition85,86, across the following four sectors: 1. academia; 2.
advocacy groups; 3. government and 4. non for-profit organizations. Stakeholders from all sectors
were affected by or affected the burden associated with AnxS in CR. This was determined by
assessing the official websites of these stakeholders for this information. In addition, all
stakeholders had relation to one or more of the 3 pillars of One Health (human, animal, and
environmental health). The second step of the approach was to provide key identification
characteristics of the stakeholders such as their location, level of function (local, regional,
national), and level of interest (field of activity, form of role, and their sector).116 Next, an
extension of existing stakeholder networks were created using “snowball sampling”.116 For the
purposes of this thesis, members of the research committee served as the first identified
stakeholders. The snowball sample framework was applied twice by using a Google search engine
to collect relevant information relating to the research team and identifying affiliated stakeholders
through the official websites of each stakeholder. The primary focus of the search was to identify
positions and organizations of the stakeholders rather than naming them. The stakeholders were
then categorized by sector, location, regional jurisdiction, field of activity/role, and rank of
influence. Rank of influence was estimated using a score between 1 (high), 2 (moderate), or 3
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(low) determined by the current position held by the stakeholder, their ability to lead research in
CR, and their ability to implement system-level changes to established guidelines and/or access to
health care services. A rank of 1 represented a high level of power/influence, a rank of 2
represented a moderate level of power/influence, and a rank of 3 represented a low level of
power/influence. The final phase of this approach was to determine possible mitigation strategies
using the stakeholders with the highest power/influence. Accordingly, identified stakeholders with
a rank of influence equal to 1 were then grouped with a reporting of their potential impact of
reducing the burden associated with AnxS in CR.
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Chapter 4
4.0.

Results

A total of 186 patients who enrolled in CR were forwarded to the research team to screen for
eligibility. Of the 186 patients, 7 patients were not eligible to join the study, 68 participants
consented to participate in the study, 59 of consented participants completed baseline
questionnaires for this study, and 31 completed 6-week follow-up questionnaires. A more detailed
breakdown can be seen below in Figure 1.

Figure 1: Cardiac Rehabilitation Participant Enrollment, Consent, and Baseline Completion of
Questionnaires
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Sociodemographic, socio-environmental, and clinical characteristics of participants who
completed baseline questionnaires were reported as presented in Table 2. Most participants were
male and under the age of 65. Sociodemographic and socio-environmental characteristics
demonstrated that most participants lived in an urban area (76.2%), were married or in commonlaw (64.4%), and were either retired or worked full-time (76.3%). Clinical characteristics
demonstrated that the top 3 reasons for referral were individuals with coronary angioplasty
(27.1%), coronary artery bypass grafting (16.9%), and (repaired) valvular heart disease (11.9%).
It is important to note that some participants may have been referred for more than 1 event. Most
participants reported a BMI (derived from reported weight and height) in the overweight (33.3%)
or obese range (31.7%), with a majority not reporting any history of diabetes (71.2%). Most
participants reported a history of hypertension (54.2%), dyslipidemia (62.7%), and CVD (62.7%).
Additionally, a vast majority of patients reported no history of a sedentary lifestyle (93.2%).

Table 2: Sociodemographic and Socio-environmental, and Clinical Characteristics of Study
Participants
N
59
Male (%) *
78.0
Age, median/mean (SD), y
64.2/63.6 (12.8)
Age group, %, y
<50
16.9
50-65
37.3
>65
45.8
Sociodemographic/Socioenvironmental Characteristics
Classification of Residing Area
Urban
76.2
Rural
22.0
Missing
1.8
Marital Status, %
Married/Common Law
64.4
Not Married
28.8
Missing
6.8
Occupational Status, %
Retired
45.8
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Full-time
Part-time
Long-term disability
Missing
Clinical Characteristics
Reason for Referral, %
CHF
CABG
Valvular Heart Disease
Coronary Angioplasty
Cardiac Arrest
MI
Unstable Angina Pectoris
Stable Coronary Artery Disease/Angina
ICD
AF
SCAD
Other
Missing
Month of Intake, %
January
February
March
April
Missing
NYHA Score, %
1 = No symptoms
2= Mild symptoms
3= marked limitation of activity due to symptoms
Missing
CCS Score, % 96
0= Asymptomatic
1= Presence of angina during strenuous, rapid, or
prolonged ordinary activity
Missing
Mean BMI, kg/m2 *
BMI category, %
<18.5 (underweight)
18.5 to 24.9 (normal)
25 to 29.9 (overweight)
30 and over (obese)
Missing
History of Hypertension, %
Yes
No
Missing
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30.5
3.4
6.8
13.5

5.08
16.9
11.9
27.1
3.4
13.5
1.7
1.7
1.7
5.1
1.7
3.4
6.82
3.4
33.9
45.8
15.2
1.7
64.4
8.5
1.7
25.4
69.5
5.1
25.4
29.8
0
15.0
33.3
31.7
20.0
54.2
44.1
1.7

History of Diabetes Mellitus, %
Yes
No
Missing
History of Dyslipidemia, %
Yes
No
Missing
Family History of CVD, %
Yes
No
Missing
Smoking Status, %
Former smoker
Current smoker
Non-smoker
Missing
History of Sedentary Lifestyle, %
Yes
No
Missing

27.1
71.2
1.7
62.7
35.6
1.7
62.7
35.6
1.7
42.4
13.6
40.7
3.3
5.1
93.2
1.7

*Missing Data
Abbreviations for Table 2 above: AF, atrial fibrillation; BMI, body mass index; CCS, Canadian Cardiovascular
Society; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CVD, cardiovascular disease;
ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NYHA, New York Heart Association; SCAD,
spontaneous coronary artery dissection

Study outcomes were tested for normality, with reported means, medians, and levels of variance.
Using a Shapiro-Wilk test, (error) distributions of physical activity, exercise capacity, resting
diastolic blood pressure, and resting systolic blood pressure deviated significantly from normality
(p<0.05). In contrast, scores of adherences to the Mediterranean diet, non-HDL-c, and HbA1c did
not deviate significantly from normality (p>0.05). A detailed description of findings can be found
below in Table 3.
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Table 3: Descriptive Statistics for Study Outcome Variables

Study Outcome
Physical Activity:
Godin Leisure-time
Activity *

Continuous Variable
Median (25th/75th
percentile) or Mean
(SD)
40.5 mins
(25.0/59.2)

Categorical Variable
Category (%)
Active
(24 pts+): 67.8

Normality
(Shapiro-Wilk
test statistic, pvalue)
Not normal
(0.740, <0.001)

Moderately Active
(14-23 pts): 10.2
Sedentary
(<14pts): 10.2

Exercise Capacity:
Duke Activity
Status Index *

7.2 METs
(5.7/9.0)

Missing: 11.8
Excellent
(10+ METs): 0

Not normal
(0.956, 0.043)

Good
(7-10 METs): 52.5
Moderate
(4-7 METs): 37.3
Poor
(1-4 METs): 3.4

Diet:
Mediterranean Diet
Questionnaire *

7.7 pts
(2.5)

Missing: 6.8
High Adherence
(10+pts): 25.0

Normal
(0.970, 0.179)

Moderate Adherence
(6-9pts): 50.0
Low Adherence
(5 or less pts): 18.3

Resting Diastolic
Blood Pressure:
Patient Health
Record *

75.0mmHg
(69.0/80.0)

Missing: 6.7
At Target
(<90mmHg): 78.0
At Risk
(>90mmHg): 1.7
Missing: 20.3
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Not normal
(0.896, <0.001)

Study Outcome
Resting Systolic
Blood Pressure:
Patient Health
Record *

Non-HDL-c:
Patient Health
Record *

Continuous Variable
Median (25th/75th
percentile) or Mean
(SD)
126.0mmHg
(114.0/140.0)

Categorical Variable
Category (%)
At Target (<140mmHg):
61.0

Normality
(Shapiro-Wilk
test statistic, pvalue)
Not normal
(0.948, 0.035)

At Risk
(>140mmHg): 18.6

3.0mmol/L (1.3)

Missing: 20.4
At Target (<2.6mmol/L):
39.0

Normal (0.964,
0.113)

At Risk
(>2.6mmol/L): 50.8

HbA1c:
Patient Health
Record *

6.0% (0.9)

Missing: 10.2
At Target
(<7.0%): 72.9

Normal (0.949,
0.191)

At Risk
(>7.0%): 15.3
Missing: 11.8
*Missing Data
Abbreviations for Table 3 above; HbA1c, hemoglobin; HDL-c, high density lipoprotein cholesterol

Study predictor variables were tested for normality, with reported means, medians, and levels of
variance. Using the Shapiro-Wilk test, study predictor variables were tested for normality. Results
suggest that AnxS, symptoms of depression, and symptoms of anxiety did not meet the criteria to
be normally distributed (p<0.001). Reports suggest that 35% of participants have moderately high
to high AnxS while most participants did not have symptoms of depression (76.3%) and anxiety
(81.4%). A detailed description of findings can be found below in Table 4.
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Table 4: Descriptive Statistics for Study Predictor Variables
Continuous
Variable
Median
Categorical Variable
Study Predictor Variable
th
th
(25 /75
Category (%)
percentile) or
Mean (SD)
Anxiety Sensitivity: ASI-3 * 12.0 (7.8, 19.0) High ‡
(22+pts): 20.0

Normality
(Shapiro-Wilk
test statistic, pvalue)

Not normal
(0.886, <0.001)

Moderately High ‡
(17-22pts): 15.0
Low ‡
(<22pts): 55.0

Symptoms of Depression:
PHQ-4 *

1.0 (0, 2.0)

Symptoms of Anxiety:
PHQ-4 *

1.0 (0, 2.0)

Missing: 10.0
High (3-6 pts) †: 22.0
Low (0-2) 76.3
Missing: 1.7
High (3-6 pts) †: 16.9
Low (0-2): 81.4
Missing: 1.7

Not normal
(0.793, <0.001)
Not normal
(0.791, <0.001)

*Missing Data
‡
Cut-points for ASI-3 were established by Allan et al. 2014 111
†
Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression
Abbreviations for Table 4 above: Anxiety sensitivity; ASI-3, Anxiety Sensitivity Index-3; PHQ-4, Patient Health
Questionnaire-4

4.1. Results: Associations between Anxiety Sensitivity, Sociodemographic,
Socio-environmental, and Clinical Characteristics
In this section, the results of analyses addressing specific aim 1 are presented.
Specific Aim 1: investigate the associations between anxiety sensitivity and
sociodemographic, socio-environmental, and clinical characteristics at initial assessment.
Hypothesis 1a: Females will have higher levels of anxiety sensitivity compared to
males.
Hypothesis 1b: Individuals with partners will have lower levels of anxiety
sensitivity compared to individuals without partners.
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Hypothesis 1c: Individuals with higher levels of anxiety sensitivity will have less
favourable clinical characteristics.

Univariate associations between AnxS, sociodemographic, socio-environmental, and clinical
characteristics were assessed using a Chi-Square test with results presented in Table 5. Results
indicated that AnxS was not significantly associated with sex, marital status, physical activity,
exercise capacity, adherence to the Mediterranean diet, resting diastolic blood pressure, resting
systolic blood pressure, non-HDL-c, and HbA1c at initial assessment (p>0.05). The association
between adherence to the Mediterranean diet and AnxS was the only study outcome to approach
statistical significance (p=0.074). This suggests that there may be a trend of individuals with high
AnxS reporting low adherence to the Mediterranean diet.

Table 5: Associations between Anxiety Sensitivity, Sociodemographic, Socio-environmental,
and Clinical Characteristics at Initial Assessment

Dependent
Variable

ASI Category:
Low (<17 pts)
(n, % within ASI
category)

Sociodemographic Characteristic
Sex *
Male: 27, 81.8

ASI Category:
Moderately High
(17-22 pts)
(n, % within ASI
category)

ASI Category:
High (>22 pts)
(n, % within ASI
category)

Male: 7, 77.8

Male: 10, 83.3

Female: 2, 22.2

Female: 2, 16.7

Married: 7, 77.8

Married: 8, 72.7

Not Married: 2, 22.2

Not Married: 3, 27.3

Active
(24+ pts): 7, 100

Active
(24+ pts): 7, 58.3

Moderately Active
(14-23 pts): 3, 10.7

Moderately Active
(14-23 pts): 0,0

Moderately Active
(14-23 pts): 3, 25.0

Sedentary

Sedentary

Sedentary

Female: 5, 15.2
Socioenvironmental Characteristic
Marital Status Married: 21, 70.0
*
Not Married: 9, 30.0
Clinical Characteristics
Physical
Active
Activity *
(24+ pts): 22, 78.6
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Significance
(Pearson ChiSquare test
statistic, pvalue)
NSS
(0.869,
0.929)
NSS
(0.211,
0.900)
NSS
(4.585,
0.333)

Dependent
Variable

Exercise
Capacity *

Mediterranean
Diet
Adherence *

Resting
Diastolic
Blood
Pressure *

Resting
Systolic
Blood
Pressure *

Non-HDL-c *

HbA1c *

(<14 pts): 3, 10.7
Excellent
(10+ METs): 0,0

ASI Category:
Moderately High
(17-22 pts)
(n, % within ASI
category)
(<14 pts): 0,0
Excellent
(10+ METs): 0,0

(<14 pts): 2, 16.7
Excellent
(10+ METs): 0,0

Good
(7-10 METs): 17, 56.7

Good
(7-10 METs): 6, 75.0

Good
(7-10 METs): 5, 41.7

Moderate
(4-7 METs): 13, 43.3

Moderate
(4-7 METs): 1, 12.5

Moderate
(4-7 METs): 6, 50.0

Poor
(1-4 METs): 0,0
High
(10+ pts): 10, 31.3

Poor
(1-4 METs): 1, 12.5
High
(10+ pts): 1, 11.1

Poor
(1-4 METs): 1, 8.3
High
(10+ pts): 3, 30.0

Moderate
(6-9 pts): 18, 56.3

Moderate
(6-9 pts): 6, 66.7

Moderate
(6-9 pts): 2, 20.0

Low
(5 or less pts): 4, 12.5
Within Target
(<90mmHg): 26, 96.3

Low
(5 or less pts): 2, 22.2
Within Target
(<90mmHg): 6, 100.0

Low
(5 or less pts): 5, 50.0
Within Target
(<90mmHg): 11,
100.0

At Risk
(>90mmHg): 1, 3.7

At Risk
(>90mmHg): 0,0

Within Target
(<140mmHg): 18,
66.7

Within Target
(<140mmHg): 6,
100.0

At Risk
(>140mmHg): 9, 33.3
Within Target
(<2.6mmol/L): 11,
39.3

At Risk
(>140mmHg): 0,0
Within Target
(<2.6mmol/L): 4, 50.0

At Risk
(>140mmHg): 2, 18.2
Within Target
(<2.6mmol/L): 5, 41.7

At Risk
(>2.6mmol/L): 4, 50.0

At Risk
(>2.6mmol/L): 7, 58.3

Within Target
(<7.0%): 7, 87.5

Within Target
(<7.0%): 9, 81.8

ASI Category:
Low (<17 pts)
(n, % within ASI
category)

At Risk
(>2.6mmol/L): 17,
60.7
Within Target
(<7.0%): 24, 82.8
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ASI Category:
High (>22 pts)
(n, % within ASI
category)

At Risk
(>90mmHg): 0,0
Within Target
(<140mmHg): 9, 81.8

Significance
(Pearson ChiSquare test
statistic, pvalue)
NSS
(6.062,
0.195)

NSS
(8.528,
0.074)

NSS
(0.644,
0.725)

NSS
(3.273,
0.195)

NSS
(0.294,
0.863)

NSS

Dependent
Variable

ASI Category:
Low (<17 pts)
(n, % within ASI
category)
At Risk
(>7.0%): 5, 17.2

ASI Category:
Moderately High
(17-22 pts)
(n, % within ASI
category)
At Risk
(>7.0%): 1, 12.5

ASI Category:
High (>22 pts)
(n, % within ASI
category)
At Risk
(>7.0%): 2, 18.2

Significance
(Pearson ChiSquare test
statistic, pvalue)
(0.125,
0.939)

*Missing Data
Abbreviations for Table 5 above: MET, Metabolic Equivalent; HbA1c, Blood Glucose; Non-HDL-c, non-high
density lipoprotein cholesterol; NSS, not statistically significant (p>0.05)

4.2. Results: Interrelationships between Anxiety Sensitivity, Anxiety,
Depression, and Clinical Characteristics
In this section, the results of analyses addressing specific aim 2 are presented.
Specific Aim 2: To investigate interrelationships among anxiety sensitivity, symptoms of
anxiety, and symptoms of depression, and how these are associated with clinical
characteristics at initial assessment.
Hypothesis 2: Individuals with higher levels of anxiety sensitivity
combined with higher symptoms of anxiety and/or depression will have less
favourable clinical characteristics.

Univariate associations between anxiety and depression, as measured using the PHQ-4, were
assessed using a Chi-Square test. The associations reported in Table 6 support that there is a
statistically significant association between the anxiety and depression subscales within the PHQ4 (p<0.05).

43

Table 6: Associations between Symptoms of Depression and Symptoms of Anxiety

Anxiety Category *

Depression
Category *

Low
(0-2 pts)

High
(3-6 pts) †

Total

Count
Within
Depression
Category (%)
Within Anxiety
Category (%)
Count
Within
Depression
Category (%)
Within Anxiety
Category (%)
Count
Within
Depression
Category (%)
Within Anxiety
Category (%)

Low
(0-2 pts)
41

High
(3-6 pts) †
4

91.1

8.9

100.0

85.4

40.0

77.6

7

6

13

53.8

46.2

100

14.6

60.0

22.4

48

10

58

82.8

17.2

100

100

100

100

Total
45

Significance
(Pearson ChiSquare test
statistic, Pvalue)
Significant
(9.816,
0.002)

*Missing Data
†
Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression

Univariate associations between AnxS and symptoms of anxiety were assessed using a Chi-Square
test. The associations presented in Table 7, support that there is a statistically significant
association between AnxS and symptoms of anxiety (p<0.05).
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Table 7: Associations between Anxiety Sensitivity and Symptoms of Anxiety

Anxiety Sensitivity Category *

Anxiety
Category *

Low
(0-2 pts)

High
(3-6 pts) †

Total

Count
Within
Anxiety
Category (%)
Within AnxS
Category (%)
Count
Within
Anxiety
Category (%)
Within AnxS
Category (%)
Count
Within
Anxiety
Category (%)
Within AnxS
Category (%)

Low
(<17 pts)

Moderate
to High
(17-22 pts)

High
(>22 pts)

Total

30

8

7

45

66.7

17.8

15.6

100.0

93.8

88.9

58.3

84.9

2

1

5

8

25.0

12.5

62.5

100.0

6.3

11.1

41.7

15.1

32

9

12

53

60.4

17.0

22.6

100.0

100.0

100.0

Significance
(Pearson ChiSquare, Pvalue)
Significant
(8.676,
0.013)

100.0

*Missing Data
†
Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression
Abbreviations for Table 7 above: AnxS, anxiety sensitivity

Univariate associations between AnxS and symptoms of depression were assessed using a ChiSquare test. The associations presented in Table 8, reported that associations between AnxS and
depression approached statistical significance (0.078).
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Table 8: Associations between Anxiety Sensitivity and Symptoms of Depression

Anxiety Sensitivity Category *

Depression
Category *

Low
(0-2 pts)

High
(3-6 pts) †

Total

Count
Within
Depression
Category (%)
Within AnxS
Category (%)
Count
Within
Depression
Category (%)
Within AnxS
Category (%)
Count
Within
Depression
Category (%)
Within AnxS
Category (%)

Significance
(Pearson
Chi-Square,
P-value)
NSS
(5.105,
Total
0.078)

Low
(<17 pts)

Moderate to
High
(17-22 pts)

High
(>22 pts)

28

5

8

41

68.3

12.2

19.5

100.0

87.5

55.6

66.7

77.4

4

4

4

12

33.3

33.3

33.3

100.0

12.5

44.4

33.3

22.6

32

9

12

53

60.4

17.0

22.6

100.0

100.0

100.0

100.0

100.0

*Missing Data
†
Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression
Abbreviations for Table 8 above: AnxS, anxiety sensitivity; NSS, not statistically significant

The implications of creating a new variable to investigate the interrelationships among the three
constructs and their impact of patient outcomes in CR can be found in the discussion section of
this thesis. A new variable was created with three categories representing the extent to which
participants had 1,2, or 3 of high AnxS, high symptoms of anxiety, and high symptoms of
depression. The “null group” were those participants with low AnxS, symptoms of anxiety, or
symptoms of depression. The “all group” were those who presented with high AnxS and high
symptoms of anxiety and high symptoms of depression. The “some group” were those who
presented with a mix of some high and some low levels of AnxS, symptoms of anxiety, or
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symptoms of depression. Of the 53 participants that had complete data for all 3 scores, there were
4 participants in the “All Group” (7.5%), 36 were in the “Some Group” (67.9%), and 13
participants were in the “Null Group” (21.7%).
Univariate associations between this new variable, representing the impact of overlapping
AnxS, symptoms of anxiety, and symptoms of depression were assessed using a Chi-Square test,
with the results presented in Table 9. There were statistically significant associations (p<0.05)
between this category and diastolic blood pressure, suggesting that individuals in the “Null” group
met the guideline recommended target significantly more frequently than individuals in the “All”
group. It is worth noting that only 1 participant in the “All” group reported not being within target.
No additional associations were found between this new variable, physical activity, exercise
capacity, Mediterranean diet adherence, resting systolic blood pressure, non-HDL-c, and HbA1c
(p>0.05).

Table 9: Associations between High Levels of Anxiety Sensitivity, Anxiety, Depression and
Clinical Characteristics at Initial Assessment

Dependent
Variable

All Group:
High AnxS, Anxiety
and Depression
(n, % within ASI
category)

Clinical Characteristics
Physical
Active
Activity *
(24+ pts): 3, 75.0

Exercise
Capacity *

Some Group:
Mix of High and/or
low AnxS, Anxiety,
and Depression
(n, % within ASI
category)

Null Group:
Low AnxS, Anxiety,
and Depression
(n, % within ASI
category)

Active
(24+ pts): 25, 83.3

Active
(24+ pts): 8, 66.7

Moderately Active
(14-23 pts): 0,0

Moderately Active
(14-23 pts): 4, 13.3

Moderately Active
(14-23 pts): 2, 16.7

Sedentary
(<14 pts): 1, 25.0
Excellent
(10+ METs): 0,0

Sedentary
(<14 pts): 1, 3.3
Excellent
(10+ METs): 0,0

Sedentary
(<14 pts): 2, 16.7
Excellent
(10+ METs): 0,0
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Significance
(Pearson ChiSquare test
statistic, pvalue)
NSS
(4.046, 0.400)

NSS
(2.994, 0.559)

Dependent
Variable

Mediterranean
Diet
Adherence *

Resting
Diastolic
Blood
Pressure *

Resting
Systolic
Blood
Pressure *

Non-HDL-c *

HbA1c *

Good
(7-10 METs): 1, 25.0

Some Group:
Mix of High and/or
low AnxS, Anxiety,
and Depression
(n, % within ASI
category)
Good
(7-10 METs): 19, 57.6

Good
(7-10 METs): 7, 58.3

Moderate
(4-7 METs): 3, 75.0

Moderate
(4-7 METs): 12, 36.4

Moderate
(4-7 METs): 5, 41.7

Poor
(1-4 METs): 0,0
High
(10+ pts): 1, 25.0

Poor
(1-4 METs): 2, 6.1
High
(10+ pts): 9, 25.0

Poor
(1-4 METs): 0,0
High
(10+ pts): 4, 36.4

Moderate
(6-9 pts): 1, 25.0

Moderate
(6-9 pts): 21, 58.3

Moderate
(6-9 pts): 4, 36.4

Low
(5 or less pts): 2, 50.0

Low
(5 or less pts): 6, 16.7

Within Target
(<90mmHg): 2, 66.7

Within Target
(<90mmHg): 27,
100.0

Low
(5 or less pts): 3,
27.3
Within Target
(<90mmHg): 13,
100.0

At Risk
(>90mmHg): 1, 33.3
Within Target
(<140mmHg): 1, 33.3

At Risk
(>90mmHg): 0,0
Within Target
(<140mmHg): 21,
77.8

At Risk
(>90mmHg): 0,0
Within Target
(<140mmHg): 11,
84.6

At Risk
(>140mmHg): 2, 66.7

At Risk
(>140mmHg): 6, 22.2

Within Target
(<2.6mmol/L): 1, 25.0

Within Target
(<2.6mmol/L): 15,
48.4

At Risk
(>140mmHg): 2,
15.4
Within Target
(<2.6mmol/L): 3,
25.0

At Risk
(>2.6mmol/L): 3, 75.0

At Risk
(>2.6mmol/L): 16,
51.6
Within Target
(<7.0%): 26, 83.9

At Risk
(>2.6mmol/L): 9,
75.0
Within Target
(<7.0%): 11, 91.7

All Group:
High AnxS, Anxiety
and Depression
(n, % within ASI
category)

Within Target
(<7.0%): 3, 75.0
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Null Group:
Low AnxS, Anxiety,
and Depression
(n, % within ASI
category)

Significance
(Pearson ChiSquare test
statistic, pvalue)

NSS
(3.844, 0.427)

Significant
(13.651, 0.001)

NSS
(3.635, 0.162)

NSS
(2.397, 0.302)

NSS
(0.767, 0.681)

Dependent
Variable

All Group:
High AnxS, Anxiety
and Depression
(n, % within ASI
category)
At Risk
(>7.0%): 1, 25.0

Some Group:
Mix of High and/or
low AnxS, Anxiety,
and Depression
(n, % within ASI
category)
At Risk
(>7.0%): 5, 16.1

Null Group:
Low AnxS, Anxiety,
and Depression
(n, % within ASI
category)

Significance
(Pearson ChiSquare test
statistic, pvalue)

At Risk
(>7.0%): 1, 8.3

*Missing Data
Abbreviations for Table 9 above: MET, Metabolic Equivalent; HbA1c, hemoglobin A1c; NSS, not statistically
significant (p>0.05)

4.3. Results: Investigating Anxiety Sensitivity as a Predictor of Change in
Physical Activity, Exercise Capacity, and Adherence to the
Mediterranean Diet
In this section, the results of analyses addressing specific aim 3 are presented. Of the 59
participants who completed baseline questionnaires, 31 (52.5%) completed 6-week follow-up
measures.
Specific Aim 3: To determine if anxiety sensitivity at initial assessment predicts change in
exercise capacity, physical activity, and diet at 6-week follow-up.
Hypothesis 3: Individuals with higher levels of anxiety sensitivity will have
smaller increases in exercise capacity, physical activity, and diet after 6-week
follow-up.
Univariate associations between AnxS, physical activity, exercise capacity, and adherence to the
Mediterranean diet at 6-week follow-up were assessed using a Chi-Square test, with results
presented in Table 10. Clinical variables presented in the table were measured once at the 6week period. No significant associations were reported (p>0.05).
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Table 10: Associations between Anxiety Sensitivity and Clinical Characteristics at 6-week
Follow-up Assessment
ASI Category:
Low
(Score <17)
(n, %)

ASI Category:
Moderately High
(Score 17-22)
(n, %)

Clinical Characteristics
Physical
Active
Activity *
(24 pts+): 13, 76.5

Active
(24 pts+): 2, 100.0

Active
(24 pts+): 6, 66.7

Moderately Active
(14-23 pts): 2, 11.8

Moderately Active
(14-23 pts): 0,0

Moderately Active
(14-23 pts): 1, 11.1

Sedentary
(<14pts): 2, 11.8
Excellent
(10+ METs): 0,0

Sedentary
(<14pts): 0,0
Excellent
(10+ METs): 0,0

Sedentary
(<14pts): 2, 22.2
Excellent
(10+ METs): 0,0

Good
(7-10 METs): 6, 46.2

Good
Good
(7-10 METs): 2, 66.7 (7-10 METs): 7, 77.8

Moderate
(4-7 METs): 7, 53.8

Moderate
(4-7 METs): 1, 33.3

Moderate
(4-7 METs): 1, 11.1

Poor
(1-4 METs): 0,0
High
(10+ pts): 5, 26.3

Poor
(1-4 METs): 0,0
High
(10+ pts): 1, 33.3

Poor
(1-4 METs): 1, 11.1
High
(10+ pts): 0,0

Moderate
(6-9 pts): 10, 52.6

Moderate
(6-9 pts): 2, 66.7

Moderate
(6-9 pts): 5, 71.4

Low
(5 or less pts): 4, 21.1

Low
(5 or less pts): 0,0

Low
(5 or less pts): 2, 28.6

Dependent
Variable

Exercise
Capacity *

Mediterranean
Diet
Adherence *

ASI Category:
High
(Score>22)
(n, %)

*Missing Data
Abbreviations for Table 10 above: MET, Metabolic Equivalent; NSS, not statistically significant (p>0.05)
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Significance
(Pearson ChiSquare test
statistic, pvalue)
NSS
(1.246, 0.870)

NSS
(5.394, 0.249)

NSS
(3.148, 0.533)

4.4.

Identified Stakeholders with Potential to Reduce Burden Associated
with Anxiety Sensitivity in Cardiac Rehabilitation

In this section, the results of analyses addressing specific aim 4 are presented.
Specific Aim 4: To identify key stakeholders within different disciplines who have the
power, influence, and potential to assist in investigating, preventing, and mitigating the
burden associated with anxiety sensitivity in CR.
After conducting a comprehensive “snowball sample” of relevant stakeholders, 21 were identified
within the academic (n=10), advocacy (n=8), government (n=1), and non-for-profit (n=2) sectors
(See Table 11 below). Identified stakeholders with an estimated rank of influence equal to 1 were
then grouped with a reporting of their potential impact of reducing the burden associated with
AnxS in CR.

Table 11: Identified Multidisciplinary Stakeholders with Potential to Reduce Risk of Burden
Associated with Anxiety Sensitivity in Cardiac Rehabilitation
Stakeholder

Location

Sector: Academia
Medical Director
London,
of CRSP at St.
Ontario
Joseph’s Health
Care London

Regional
Jurisdiction
Local,
provincial,
national,
global

Director of CPRP
at Toronto
Rehabilitation,
UHN

Toronto,
Ontario

Local,
provincial

Director of
Research, CR,
Peter Munk
Center, UHN

Toronto,
Ontario

Local,
provincial,
national,
global
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Field of Activity/Role
Works clinically and
academically to reduce
burden, and improve
clinical outcomes
associated with CR
An expert on the impact
of exercise in CR. Works
clinically and
academically to reduce
burden, and improve
clinical outcomes
associated with CR
Works academically to
optimize patient
outcomes in post-acute
cardiovascular care

Rank of
Influence
1 (High)

1 (High)

1 (High)

Stakeholder

Location

Clinical
Psychologist
involved in CR

London,
Ontario

Beryl and Richard
Ivey Research
Chair in aging,
mental health,
rehabilitation, and
recovery
Beryl Ivey Chair
of One Health

London,
Ontario

Western
University

London,
Ontario

One Health
Institute

Guelph,
Ontario

Ontario
Veterinary
College

Guelph,
Ontario

Guelph University

Guelph,
Ontario

London,
Ontario

Sector: Advocacy Groups
Senior Vice
Toronto,
President of
Ontario
CorHealth Ontario

President of the
CACPR

Regional
Rank of
Field of Activity/Role
Jurisdiction
Influence
Local,
Extensive knowledge in
2 (Moderate)
provincial,
Cardiovascular health
national
and the influence of
psychology
Local,
Contributed academically 2 (Moderate)
provincial,
to the use of mental
national,
health technology for
global
individuals with
depression
Local,
provincial,
national, and
global
Local,
provincial,
national, and
global
Local,
provincial,
national, and
global
Local,
provincial,
national

Local,
provincial,
national, and
global
Provincial

Saskatoon,
National
Saskatchewan
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One Health Advocate

3 (Low)

Encourages One Health
through academic
research and student-led
committees
Promotes academic,
research, and outreach
programs related to One
Health
Works clinically and
academically with animal
health. Potential to
advance translational
research on the influence
of AnxS on
cardiovascular disease
Encourages One Health
through academic
research and student-led
committees

3 (Low)

Primary focus on
healthcare policy and
planning improvement.
Facilitated collaboration
between CCN and OSN
organizations, leading to
the founding of
CorHealth
Enhances knowledge,
clinical care, and

1 (High)

3 (Low)

3 (Low)

3 (Low)

1 (High)

Stakeholder

Location

Interim Chair of
CRNO

Ottawa,
Ontario

Vice President of
CorHealth Ontario

Toronto,
Ontario

Regional
Jurisdiction

Local,
provincial,
national
Provincial

Local

Student-led committee
advocating for the
importance of One
Health

3 (Low)

Provincial

Responsible for
governing and managing
the healthcare system on
Ontario population-level

1 (High)

Acknowledge the
influence of social
determinants of health on
mental health outcomes.
Has 7 years of
experience working on a
multi-stakeholder.
Leading funder for
cardiovascular related
research. Potential to
invest in research
targeting AnxS for
treatment in CR

1 (High)

Director-general
of WHO

Geneva,
Switzerland

Global

One Health Club

London,
Ontario
Guelph,
Ontario

Local

Sector: Non-Profit/Voluntary Organizations
National Chief
Toronto,
Local,
Executive Officer Ontario
provincial,
of CMHA
national

CEO of Heart and
Stroke Foundation

Ottawa,
Ontario

1 (High)

2 (Moderate)

Provincial

Sector: Government
Minister of Health Toronto,
in Ontario
Ontario

research within the scope
of CR
Focuses on care provided
by CR program.

Rank of
Influence

Works to fulfill
CorHealth mandate of
improving the healthcare
system by leading the
clinical and digital teams.
Works on psychotherapy
treatments on range of
mental health disorders.
Potential to investigate
the targeting of AnxS
Launched Mental Health
Initiative for Universal
Coverage
One Health Advocate

Clinical
St.
Neuropsychologist Catherine’s,
staff member on
Ontario
OPA

One Health
Student
Committee

Field of Activity/Role

National
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2 (Moderate)

3 (Low)

3 (Low)

2 (Moderate)

Abbreviations for Table 11 above: AnxS, Anxiety sensitivity; CACPR, Canadian Association of Cardiovascular
Prevention and Rehabilitation; CCN, Cardiac Care Network; CMHA, Canadian Mental Health Association; CPRP,
Cardiovascular Prevention and Rehabilitation Program; CR, Cardiac rehabilitation; CRNO, Cardiac
Rehabilitation Network of Ontario; CRSP, Cardiac Rehabilitation and Secondary Prevention; NGO, Nongovernmental organization; OPN, Ontario Psychological Association; OSN, Ontario Stroke Network; UHN,
University Health Network; WHO, World Health Organization

Table 12: Identified Stakeholders with the Highest Estimated Potential Power and Influence
Stakeholder

Regional Jurisdiction

Health Minister of Ontario

Provincial

Medical Director of CRSP
Program at St. Joseph’s
Health Care London

Local, provincial

Director of CPRP at Toronto
Rehabilitation, UHN

Local, provincial

Director of Research, CR,
Peter Munk Center, UHN

Local, provincial

Senior Vice President of
CorHealth Ontario

Provincial
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Potential Impact of Direct
Influence
Potential to administer
funding and provide access to
support psychological
services aimed to treat AnxS
in CR.
Ability to conduct a
collaborative clinical trial
with Toronto Rehabilitation
on the efficacy of treating
AnxS in CR. This stakeholder
also has established
relationships with members
of the CACPR. This may help
with implementing changes to
the CACPR guidelines if
AnxS treatment provides
clinical benefit.
Ability to conduct a
collaborative clinical trial
with CRSP program at St.
Joseph’s Health Care London
on the efficacy of treating
AnxS in CR.
This stakeholder is an active
member of the CACPR. They
have the potential to
communicate the efficacy of
AnxS treatment to board
members, with efforts to
modify guidelines where
applicable.
Potential to advocate for
guideline modifications,
communicating evidence-

President of the CACPR

National

Interim Chair of CRNO

Local, provincial

National Chief Executive
Officer of CMHA

Local, provincial, national
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based recommendations of
treating AnxS to the CACPR.
Potential to lead and
implement changes to the
CACPR on the burden
associated with AnxS,
grounded by evidence-based
research conducted by
clinical trials.
Potential advocate to the
CACPR on guideline
modifications relating to
treatment of AnxS.
Potential to guide
engagement of stakeholders
involved.

Chapter 5
5.0.

Discussion

This longitudinal cohort study, despite being curtailed by the COVID-19 pandemic to 59
participants, provides a novel evaluation of relationships between AnxS and patient outcomes in
CR.

5.1. Characteristics of the Study Sample
Due to COVID-19, CR was completed virtually by patients. Subsequently, participation in this
study was also completed virtually, making this group of participants a unique “COVID-19
cohort”. As a direct consequence to delays in clinical care due to COVID-19, research activities
were also delayed, impacting the number of participants enrolled in this study. Therefore, it is
important that enrollment continues beyond the completion of this thesis to increase the statistical
power of this study. Of eligible patients, about 38% consented to participate in the study. Of the
participants who consented, 87% completed questionnaires at initial assessment, and of the
participants who completed questionnaires at initial assessment, about 53% completed follow-up
surveys. This data speaks to study performance of this cohort. Despite a low sample size, clinical
characteristics (i.e., age and reason for referral) of this cohort were consistent with similar studies
done in CR.83,84 However, this cohort was more physically active and presented with a good level
of exercise capacity at initial assessment than anticipated. This may have been due to this cohort
being a relatively younger sample compared to other CR samples, as approximately 20% of the
cohort was under the age of 50. Results also suggested that a vast majority of participants (75%),
moderately adhered to the Mediterranean diet. Results also suggested that about half of the
participants (50.8%) did not meet the guideline recommended target for blood lipid control (non-
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HDL-c), while most participants (72.9%) attained the guideline recommended target for blood
glucose control (HbA1c) at baseline. This suggests that this cohort may be healthier than other CR
cohorts but needs further investigation to support this claim.

5.2. Anxiety Sensitivity and Patient Outcome Characteristics
Previous studies have reported associations between gender and AnxS, suggesting that women
report significantly higher AnxS compared to men. Inconsistent with those findings and our
hypothesis, sex and physical activity were not significantly associated with AnxS in this study.
This may be due to the current study investigating these relationships in CR in which previous
studies did not. Additionally, the sample size reporting sex was low (n=58), creating implications
for statistical power. Future studies should re-test this association with a larger sample size to
ensure these findings are accurate. Previous studies have also reported associations between
physical activity and AnxS, suggesting that individuals more physical active report significantly
lower AnxS compared to those who are sedentary. Based on our cohort being more active than
anticipated, we did expect to detect an association. However, physical activity was not associated
with AnxS. This may be due to much of the literature reporting associations in a younger and nonclinical population. It may also be due to a low sample size of those reporting level of physical
activity (n=47). Future studies should re-test this association with a larger sample size to ensure
these findings are accurate. Interestingly, results indicate that individuals with high AnxS may
have low adherence to the Mediterranean diet, however it does warrant further study and additional
sample size to ensure that this was not a spurious observation. No other associations between AnxS
and the remaining socio-environmental and clinical characteristics were found, which were not
expected. This may also be due to lack of statistical power, therefore, these associations merit
further investigation with a larger sample size to ensure these findings are accurate. If significant
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associations are found with a larger sample size, this may suggest the need to target AnxS for
treatment, as individuals with high AnxS will be less likely to report favourable patient outcomes
in CR.

5.3. Anxiety Sensitivity, Anxiety, and Depression
Previous studies have reported associations between AnxS, anxiety, and depression. Consistent
with the findings from the literature, results from this study reported 2 key relationships.
Significant associations between symptoms of depression and symptoms and anxiety were
observed in this cohort as expected, and consistent with previously reported observations.117 More
importantly, reported significant associations between AnxS and symptoms of anxiety in this study
may provide clinical implications in CR. Based on the literature, we expected significant
associations between AnxS and symptoms of depression, however, this association only
approached significance likely due to low statistical power. With symptoms of anxiety and
depression being routinely screened and treated in CR, the need to understand whether routine
screening and treatment of AnxS in CR is beneficial merits further investigation. With insufficient
sample size to investigate the interrelationships among AnxS, symptoms of anxiety, symptoms of
depression, and their impact on patient outcomes in CR, the creation of a new variable was a
preliminary step used to address this question with the data obtained. Additionally, associations
between AnxS, the “All”, “Some”, and “Null” groups, suggest that individuals with high AnxS,
and positive PHQ-4 screens on symptoms of anxiety and depression, reported a resting diastolic
blood pressure outside of the recommended target range. No other associations between AnxS,
symptoms of anxiety and depression, and additional CR clinical characteristics were found. Based
on the findings of association between AnxS, depression, and anxiety, we expected to see more
associations between AnxS and the study outcomes. However, we did not observe these
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associations potentially due to lack of statistical power. Future studies should evaluate the same
associations with a larger sample size to ensure the relationships observed are accurate.

5.4. Anxiety Sensitivity and Clinical Progress in Cardiac Rehabilitation
Currently, the literature suggests that AnxS is a predictive marker for change in exercise
behaviour.68 We expected that AnxS at initial assessment would be a predictive marker for change
in physical activity at 6-week follow-up, however no significant associations were found.
Moshier’s study involving a much younger cohort68 may explain why no relationship was observed
as the cohort in this thesis was significantly older than that of Moshier’s. Secondly, only 31
participants completed follow-up questionnaires, indicative of low statistical power. Additionally,
AnxS at initial assessment did not predict physical activity, exercise capacity, and adherence to
the Mediterranean diet at 6-week follow-up.
Strong evidence suggests that CR improves patient outcomes and reduces burden related
to CVD.4 Despite the efficacy of CR, individuals with high AS have reported fear or exercise
which may be related to CR dropout.83 If AnxS at baseline is proven to be a predictive marker for
clinical characteristics at 6-week follow-up, this may provide a better a predictor for CR dropout,
supporting the need to treat AnxS. The evaluation of this relationship with a larger sample size
merits further investigation which may provide clinical implications.

5.5. Stakeholder Implications
Stakeholders play an essential role both independently and collaboratively in improving patient
outcomes associated with AnxS in CR. The RECARE approach has been an effective framework
for identifying stakeholders in a systematic and collaborative style as indicated with the RECARE
project.116 The RECARE project was applied to a large transdisciplinary research project, where a
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broad network of stakeholders was created.116 This approach allowed for stakeholder identification
to be directly part of the research methodology by establishing criteria for stakeholder
identification and allowing identified stakeholders to recruit potential stakeholders who could
positively impact the outcomes of the study. Using this process, stakeholder implications in this
thesis were more applicable to the research question.
Research, advocacy, and policy modifications are common themes seen across many key
stakeholders that aim to effectively support the healthcare needs of patients enrolled in CR.
Academia has proven to be essential in conducting research relevant to cardiovascular health. To
reduce the burden associated with AnxS, clinicians and researchers are on the forefront of
conducting clinical trials to target AnxS for treatment within CR. Additionally, provincial
healthcare providers with executive roles provide population-level benefit as they often are
involved in overseeing the clinical and economic decisions related to improving the healthcare
system. The provincial government is another example of a potential stakeholder that carries high
power and influence. Resource allocation to support clinical trials and possible changes to routine
care in CR is one way they can make a clinical impact.
Based on these findings, categorizing identified stakeholders based on level of influence,
interest, and power is both an efficient and effective way to reduce the burden associated with
AnxS in CR, as those with higher influence, interest, and power, will likely provide substantial
impact.

5.6. Strengths and Limitations
The strengths of this study include its novelty along with its prospective study design – information
obtained from this study will be relevant for individuals that have been recently diagnosed with or
that currently suffer from a cardiac condition. The prospective aspect of the study will allow us to
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draw casual inferences about the potential to target AnxS for treatment for those enrolled in a CR
program. By observing the impact of AnxS on socio-environmental, sociodemographic, and
clinical characteristics, this study is novel in applying a One Health approach to investigate a
research problem specific to CR. Identification of multisectoral stakeholders highlighted an
additional key element of the One Health approach and may allow future studies to test the efficacy
of stakeholder engagement in improving patient outcomes in CR. Due to the impact of COVID19, the findings from this study should be interpreted with a few limitations in mind. Firstly,
selection bias may have impacted this study in the following ways: a. the pandemic may have been
related to why the cohort was relatively younger compared to previous CR cohorts – this may have
played a role in higher than expected fitness of the sample; b. a long delay of intake into CR had
an unknown effect on patients who agreed to wait to enroll in CR – this may have impacted
associations reported in Chapter 4; c. virtual care in CR may have added unknown implications of
enrolled patients as prescribed exercises, for example, were not routinely monitored; and d. lower
enrollment of those eligible to participate in CR directly impacted the number of eligible patients
for this study. Psychological measurements during this study may have also been affected by
conditions caused by COVID-19 – this could include feelings of hopelessness, anxiousness, and
little to no interest in doing things, which are characteristics evaluated through the PHQ-4. Future
analysis of this study should aim to compare PHQ-4 scores from this cohort to a previous “nonCOVID” cohort. Additionally, this study did not account for participants who could have been
undergoing CBT treatment for AnxS. Future analysis should take this into consideration when
interpreting the results. A stakeholder limitation was the use of the snowball sampling method. All
stakeholders were identified from one source as opposed to obtaining them from initially identified
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stakeholders. Future research should aim to include direct involvement of stakeholders when
creating a multidisciplinary network of stakeholders.

5.7. Contributions and Future Directions
To date, this is one of the first prospective studies to investigate the relationships between AnxS
and patient outcomes in CR, and the first study to investigate this relationship during the COVID19 era, as previous studies have investigated similar relationships cross-sectionally. Benefits to
this study design allowed for changes in characteristics to be evaluated in the target population.
However, based on the findings of this study, repeating this study with a larger sample size postpandemic may provide more substantial support for the need to routinely assess AnxS in CR if
significant associations are reported.
This study is also one of the first studies to identify transdisciplinary stakeholders with high
power, influence, and interest in investigating, preventing, and mitigating the burden associated
with AnxS in this study population. While evidence supports the effectiveness of using the One
Health approach to implement change within the realm of infectious disease, many aspects of the
approach can be transferred to non-communicable diseases. Future studies should directly engage
with identified stakeholders to conduct clinical trials on treating AnxS in CR, translating the results
of the clinical trial to the appropriate stakeholders, and implementing system-level changes to
routine care, allowing for AnxS to be routinely evaluated alongside symptoms of anxiety and
depression.
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Chapter 6
6.0.

Conclusion

This study provides some evidence for the importance of evaluating AnxS in CR. Although no
significant associations were reported between AnxS, sociodemographic, socio-environmental, or
clinical characteristics, we were able to provide some evidence of association between AnxS and
adherence to the Mediterranean diet. We were also able to provide evidence consistent with the
literature of significant associations between symptoms of anxiety and symptoms of depression,
significant associations between AnxS and anxiety, and some evidence of association between
AnxS and depression. We were also able to provide evidence of the associations between resting
diastolic blood pressure and the combined presence of high AnxS, a positive screen for symptoms
of depression, and a positive screen for symptoms of anxiety as reported by the PHQ-4. This
association was based on a small sample size and must be re-evaluated using a larger sample.
Important to the One Health approach, we were able to provide evidence of powerful and
influential stakeholders that may assist in reducing the burden associated with AnxS in CR.
Unfortunately, due to a small sample size, most analyses lacked the statistical power
to be thoroughly investigated. As a result of these findings, we propose that a larger sample size is
needed to observe more accurate findings of this study. Additionally, the significant associations
reported in this study also lacked statistical power and should also be re-analysed with a larger
sample size and with different parametric tests (i.e., t-test and regression) to ensure reported results
are accurate. We also propose that snowball sampling of stakeholders be obtained directly from
previously identified stakeholders as potentially stronger collaborations and networks may exist.
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Appendix B
6-month Cardiac
Rehabilitation &
Secondary Prevention
(CRSP)Program

Red font indicates a transition to
virtual care

Levels of Technology Capability

INTAKE
OTN video
conference

OR attend recorded orientation
session (appt. type: orientation-rec)

Flow Diagram of Virtual Care Process for CR and Levels of Technology Capability
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Referral
Patient Enrolled
Into Study
Standard information package
sent prior to 1st virtual
appointment. Within the
package is an REB approved
pamphlet notifying patients
that they may be contacted to
participate in the study

Patient “opts out” of
research documentation made in
patient chart

Review
questionnaire
scores for
‘positive
screen’ criteria
for depression
or distress

Make initial appointment for
baseline primary data collection
(ASI-3, *PHQ-4, *GODIN, *DASI,
and *Mediterranean Diet
Questionnaire)

Patients completes the virtual
intake appointment
Reminder for
data collection
appointment

Patient not
considered for
enrolment into the
study

Patient is not eligible

Patients
Screened
for
Eligibility in
the Study

2nd appointment at week
7 for primary data
collection

Patient is eligible

Review
questionnaire
scores for
‘positive screen’
criteria for
depression or
distress

Secondary Data Collection

Data abstracted
from
Cardiologica
and patient’s
medical records

Reminder for
data collection
appointment
Patient not
considered for
enrolment into the
study

Patient is not interested in
joining the study

Contact eligible
patient to ask if
they are
interested in
participating in
the study

3rd appointment at week
13 for primary data
collection

Patient is interested in
joining the study

Reminder for
data collection
appointment

Patient is sent letter of
information to review via
mail or e-mail

Patient Not
Enrolled

Patient does not provide
informed consent

Informed
Consent
(verbal via
telephone)

4th appointment at week
19 for primary data
collection

Reminder for
data collection
appointment

Patient provides
informed consent
Participant receives copy of signed
Informed Verbal Consent by Mail
or E-mail

*The PHQ-4, GODIN, DASI, and the Mediterranean
Diet Questionnaire are administered as part of
standard care. However, due to COVID-19 and the
recent changes to care, it is not being reliably or
routinely assessed in every patient – they are now
being added to this research protocol.

Review
questionnaire
scores for
‘positive
screen’ criteria
for depression
or distress

Final appointment for
discharge primary data
collection

Patient Enrolled
Into Study (Unique
Study # assigned)

Review
questionnaire
scores for
‘positive
screen’ criteria
for depression
or distress

Review
questionnaire
scores for ‘positive
screen’ criteria for
depression or
distress

Study
Participation
Complete

Flow Diagram of Patient Enrollment and Data Collection Methodology
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Clinical characteristics
assessed at baseline – these
include but are not limited to
BP, blood sugar, blood
cholesterol, smoking status,
and medication

Clinical characteristics, and
CRSP participation and
completion (primary study
outcome), assessed at
discharge

Copy of Initial Call Script (Page 1)
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Copy of Initial Call Script (Page 2)
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Copy of Letter of Information (Page 1)
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Copy of Letter of Information (Page 2)
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Copy of Letter of Information (Page 3)
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Copy of Letter of Information (Page 4)
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Copy of Verbal Consent Documentation (Page 1)
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Copy of Verbal Consent Documentation (Page 2)
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Appendix C
Anxiety Sensitivity Index – 3 (ASI-3) Questions and Factor Categories
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Patient Health Questionnaire – Four (PHQ-4) Questions and Scoring
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Godin Leisure-Time Questionnaire – Instructions for Scoring
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Godin Leisure-Time Questionnaire – Items included

87

Duke Activity Status Index (DASI) – Questions and Scoring

88

Mediterranean Diet Questionnaire - Questions and Scoring
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Appendix D
Original Aims and Hypotheses
Specific Aim 1: To investigate the associations between anxiety sensitivity and cardiac
rehabilitation and secondary prevention clinical outcomes for patients participating in the
cardiac rehabilitation and secondary prevention program.
Hypothesis 1a: Individuals with higher levels of anxiety sensitivity at the beginning
of a cardiac rehabilitation and secondary prevention program will have lower levels
of participation and will be less likely to complete the program.
Hypothesis 1b: Individuals with higher levels of anxiety sensitivity at the beginning
of a cardiac rehabilitation and secondary prevention program will be less likely to
attain the expected therapeutic targets for the program, including exercise capacity,
blood pressure control, and blood lipid control.
Specific Aim 2: To investigate changes in anxiety sensitivity during the course of a cardiac
rehabilitation and secondary prevention program, and how these changes in anxiety
sensitivity are associated with clinical outcomes for patients participating in a cardiac
rehabilitation and secondary prevention program.
Hypothesis 2a: Anxiety sensitivity will decrease during the course of a cardiac
rehabilitation and secondary prevention program.
Hypothesis 2b: Individuals with higher reductions in anxiety sensitivity will have
higher levels of participation and will be more likely to complete a cardiac
rehabilitation and secondary prevention program.
Hypothesis 2c: Individuals with higher reductions in anxiety sensitivity will be
more likely to attain the expected therapeutic targets for a cardiac rehabilitation and
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secondary prevention program including, exercise capacity, blood pressure control,
and blood lipid control.
Specific Aim 3: To investigate the interrelationships between anxiety sensitivity,
symptoms of anxiety, and symptoms of depression, and how these interrelationships are
associated with clinical outcomes for patients participating in a cardiac rehabilitation and
secondary prevention program.
Hypothesis 3a: In some individuals, anxiety sensitivity will be present, fully
independent of symptoms of anxiety and symptoms of depression
Hypothesis 3b: Individuals with higher levels of anxiety sensitivity will be more
likely to report symptoms of anxiety and symptoms of depression
Hypothesis 3c: Individuals with the concurrent presence of anxiety sensitivity,
symptoms of anxiety, and symptoms of depression, will have the lowest levels of
participation and completion
Hypothesis 3d: Individuals with the concurrent presence of anxiety sensitivity,
symptoms of anxiety, and symptoms of depression will be less likely to attain the
expected therapeutic targets for a cardiac rehabilitation and secondary prevention
program including increased exercise capacity, blood pressure control, and blood
lipid control.
Specific Aim 4: To identify key stakeholders, individuals or groups who have an interest
in or the ability to act upon the results of the study in order to optimize the health of Cardiac
Rehabilitation and Secondary Prevention patients.
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Specific Aim 5: To create a map of identified stakeholders that assists in visualizing the
relationships between stakeholders, their organization affiliations, and their relative
influence.
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• Created 50-page study protocol comprised of background information and the
materials and methods of my study
• Initiated and completed the “Research Ethics Approval” (REB) process for my
study
• Experience with working with hospital approved, REDCap platform, used to setup survey tools and collect both clinical data and survey data
• Experience with performing literature searches across multiple health-related
databases
• Developed the ability to critique high and low impact research papers in order to
gain the skills and understanding to create and develop my own manuscript
• Attended monthly seminars under the Pathology and Laboratory Medicine
Department, tuning into guest speakers discuss clinical research relevant to the field
of Pathology
• Attended weekly research meetings with the CRSP research team to discuss
progress with my research project and other research projects being conducted in the
program
• Advisory Committee meetings held every 6-months to update members of my
research team with project milestones.
Summer Research Student
May 2017-August 2017
Microbiology Department

Mount Sinai Health System, Toronto, ON
• Created standard operating procedures with superiors
• Collected data in Excel to validate the ACCELERATE PHENO System to detect
susceptibility of hospital bacteria to various antimicrobial agents
• Ran the BioFire FilmArray Multiplex PCR System on blood samples to detect for Candida
species
• Used SHIGA TOXIN QUIK CHEK to detect Shiga toxins in E. coli species via agglutination
techniques
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Created Validation report for QUIK CHEK
• Practiced technical skills such as streaking, plating, creating 0.5 McFarlan, and using
selective agars
• Exposed to microbiology related lab instruments such as the MALDI-TOF and VITEK
machinery
• Gave mini presentation to supervisors and employees of the department summarizing the
projects and work done over the course of my employment
VOLUNTEER EXPERIENCE
May 2016 – August 2016

Outpatient Physiotherapy Volunteer

William Osler Health System
Etobicoke General Hospital
Duties included:
• Reviewed patient charts prior to their arrival in order to set and prep the
following item(s):
o Preparing patient beds
o Prepping heat/cooling pads
o Prepping exercise stretch bands based on incoming patient
schedule
• Talked to patients as they completed their designated exercise routines
• Demonstrated leadership when new volunteers came to the clinic –
assisted them in becoming more familiar with how the clinic is run
• Worked in collaboration with physiotherapists, physiotherapist assistance
and other volunteers in order to deliver standard of care

INTERPERSONAL AND TEACHING EXPERIENCE
Graduate Teaching Assistant

September 2020-Present

Department of Pathology and Laboratory Medicine

The University of Western Ontario, London, ON
Course: One Health 3300 – Foundations to One Health
• Objective was to mark weekly quizzes related to conceptual frameworks, socialism,
environmental health, animal health, human health, and their interconnectedness
• Course: One Health 3600 – One Health in Action
•
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Objective is to continue working on the well-developed proposals from the One Health
3300 class and assist students to work on and finalize an “action-plan” project to
implement the One Health approach to a non-infectious or infectious disease related case.

Undergraduate Teaching Assistant

September 2018-December 2018

School of Interdisciplinary Science (SIS)

McMaster University, Hamilton, ON
• Course: Science 1A03 – Investigating Science: Opportunities & Experiences
• Objective was to help first year university students prepare for the university career
through different avenues
• Lead in class sessions three times a week on applying basic research skills to analyzing
scientific articles, working on mini-projects, and creating reflections
• Shed insight on my own experiences as an undergraduate as a way to facilitate discussion
COMMUNICATIONS EXPERIENCE
Pathology and Laboratory Medicine Research Day
April 2021
Department of Pathology and Laboratory Medicine
Western University, London, ON
• Conducted a 3-minute poster presentation of my master’s thesis followed by a 2-minute
Q&A period
Health & Rehabilitation Sciences Graduate Research Conference
February 2021
Western Health Sciences
Western University, London, ON

• Conducted a 5-minute oral presentation of my master’s thesis
One Health Poster Day
November 2020
The Centre for Public Health and Zoonoses and the One Health Institute at the University of
Guelph, in collaboration with the One Health Program in the Department of Pathology and
Laboratory Medicine at the Schulich School of Medicine & Dentistry at Western University
The University of Guelph
• Conducted a 2-minute live oral presentation via Microsoft Teams of my master’s
thesis
• Had the opportunity to gain constructive feedback regarding my study and gain
insight on other research projects relevant to One Health
One Health Poster Day
November 2019
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The Centre for Public Health and Zoonoses and the One Health Institute at the University of
Guelph, in collaboration with the One Health Program in the Department of Pathology and
Laboratory Medicine at the Schulich School of Medicine & Dentistry at Western University
The University of Guelph
• Conducted In-Person Poster Presentation of my master’s thesis
• Had the opportunity to gain constructive feedback regarding my study and gain
insight on other research projects relevant to One Health
Physician Observership
Oncology
Juravinski Cancer Centre, Hamilton, Ontario
•
•
•
•
•

September 2018-December 2018

Visited patient rooms with Dr. Dhesy and observed her role as a medical oncologist
Observed breast exams, body CT’s, and patient history
Shadowed the work of the current medical residents in the department
Examined the roles of other practitioners that worked alongside Dr. Dhesy
Completed a placement project summing everything learned over the 4-month span

Summer Student Research Day
August 2017
Mount Sinai Health System, Department of Microbiology
Toronto, Ontario
• Conducted a 15-minute oral presentation to supervisors and employees of the department
summarizing the projects and work done over the course of my employment at Mount
Sinai Hospital
PUBLICATIONS
Scoping Review – 1st Author
Present
Pathology and Laboratory Medicine Department

The University of Western Ontario, London, ON
• Manuscript (In Progress): The Relationship Between Anxiety Sensitivity and
Outcomes in Cardiac Rehabilitation – A Scoping Review
LEADERSHIP
Mentor for Pathology and Laboratory Medicine Program
Western University
London, Ontario

September 2020-Present

• Currently a mentor in the PaLM Program at Western University as a graduate student. I meet
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with a 1st year MSc. student monthly to discuss any questions or advice he might need as well
as providing social support, advocating for the importance of mental health especially during
these uncertain times.
Mentor and Alumnus of MOTION Basketball Association
September 2014-Present
Rexdale, Ontario
• Attend yearly events to speak to at-risk youth about relatable experiences and how to go
about making a change in the community
Summer Science Camp Counsellor
June 2019-August 2019
YMCA (GTA), Mississauga, Ontario
• Ran Camps for 7 weeks, running science activities for junior (ages 5-8) and senior (ages 912) children. Science experiments range from making "slime" and other hands-on activities
to performing chemical reactions for the older and more advanced groups. I was not only a
teacher but learned to become a mentor for both kids and other staff.
Member of the Black Aspiring Physicians of McMaster Association
September 2016-April 2019
McMaster University
Hamilton, Ontario
• Being part of the Black Aspiring Physicians of McMaster Association, I was able to both
receive and give mentorship to fellow undergraduate students who identify as Black, hoping
to pursue a career in healthcare.

SKILLS & CERTIFICATIONS
• Certified in Standard First Aid & CPR/AED Level C – Canadian Red Cross
• Certified in WHMIS Training – Western University
• Certified in Tri-Council Policy Statement (TCPS 2: Core): Ethical Conduct for Research
Involving Humans Course on Human Ethics
• Certified in Animal Ethics and Regulation – Western University
• Certified in Supervisor Health and Safety Awareness – Western University
• Certified in AODA: Accessibility and Service – Western University
• Proficient in all Microsoft applications
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